Vaccine Immunology

**2**

*Claire-Anne Siegrist*

To generate vaccine-mediated protection is a complex chal- lenge. Currently available vaccines have largely been devel- oped empirically, with little or no understanding of how they activate the immune system. Their early protective efficacy is primarily conferred by the induction of antigen-specific anti- bodies ([Box 2.1](#_bookmark0)). However, there is more to antibody- mediated protection than the peak of vaccine-induced antibody titers. The quality of such antibodies (e.g., their avidity, specificity, or neutralizing capacity) has been identi- fied as a determining factor in efficacy. Long-term protection requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells capable of rapid and effective reactivation with subsequent microbial exposure. The determinants of immune memory induction, as well as the relative contribution of persisting antibodies and of immune memory to protection against spe- cific diseases, are essential parameters of long-term vaccine efficacy.

The predominant role of B cells in the efficacy of current

vaccines should not overshadow the importance of T-cell responses: T cells are essential to the induction of high-affinity antibodies and immune memory, directly contribute to the protection conferred by current vaccines such as bacille Calmette-Guérin (BCG), may play a more critical role than previously anticipated for specific diseases like pertussis, and will be the prime effectors against novel vaccine targets with predominant intracellular localization such as tuberculosis.

New methods have emerged allowing the assessment of a growing number of vaccine-associated immune parameters, including in humans. This development raises new questions about the optimal markers to assess and their correlation with vaccine-induced protection. The identification of mechanistic immune correlates—or at least surrogates—of vaccine efficacy is a major asset for the development of new vaccines or the optimization of immunization strategies using available vac- cines. Thus, their determination generates a considerable amount of interest. During the last decade, the increased awareness of the complexity of the immune system and its determinants, including at the host genetic level, indicated that using system biology approaches to assess how various processes and networks interact in response to immunization could prove more illustrative than trying to isolate and char- acterize a few components of vaccine responses.1 Delineating the specific molecular signatures of vaccine immunogenicity is beginning to highlight novel correlates of protective immu- nity and better explain the heterogeneity of vaccine responses in a population. The tailoring of vaccine strategies for specific vulnerable populations, including very young, elderly, and immunosuppressed populations, also largely relies on a better understanding of what supports or limits vaccine efficacy under special circumstances—at the population and individ- ual levels. Lastly, the exponential development of new vaccines raises many questions that are not limited to the targeted diseases and the potential impacts of their prevention, but that address the specific and nonspecific impacts of such vaccines on the immune system and, thus, on health in general. These immune-related concerns have largely spread into the population, and questions related to the immunological safety of vaccines—that is, their capacity for triggering

### 16

non–antigen-specific responses possibly leading to allergy, autoimmunity, or even premature death—are being raised. Certain “off-targets effects” of vaccines have also been recog- nized and call for studies to quantify their impact and identify the mechanisms at play. The objective of this chapter is to extract from the complex and rapidly evolving field of immu- nology the main concepts that are useful to better address these important questions.

# HOW DO VACCINES MEDIATE PROTECTION?

Vaccines protect by inducing effector mechanisms (cells or molecules) capable of rapidly controlling replicating patho- gens or inactivating their toxic components. Vaccine-induced immune effectors ([Table 2.1](#_bookmark1)) are essentially antibodies— produced by B lymphocytes—capable of binding specifically to a toxin or a pathogen.2 Other potential effectors are cyto- toxic CD8+ T lymphocytes that may limit the spread of infec- tious agents by recognizing and killing infected cells or secreting specific antiviral cytokines and CD4+ T-helper (Th) lymphocytes. These Th cells may contribute to protection through cytokine production and provide support to the gen- eration and maintenance of B and CD8+ T-cell responses. Effector CD4+ Th cells were initially subdivided into T-helper 1 (Th1) or T-helper 2 (Th2) subsets depending on their main cytokine production (interferon-γ or interleukin [IL]-4), respectively. This dichotomy became outdated as Th cells were increasingly shown to include a large number of subsets with distinct cytokine-producing and homing capacities (see [Table](#_bookmark1) [2.1](#_bookmark1)).3 A recently identified critical subset of vaccine-induced CD4+ Th cells are follicular T-helper (Tfh) cells: they are spe- cially equipped and positioned in the lymph nodes to support potent B-cell activation and differentiation into antibody- secreting-cells4 and were identified as directly controlling anti- body responses and mediating adjuvanticity.5–7 Another important subset are T-helper 17 (Th17) cells which essen- tially defend against extracellular bacteria that colonize the skin and mucosa, recruiting neutrophils and promoting local inflammation.8,9 These effectors are controlled by regulatory T cells (Tregs) involved in maintaining immune tolerance.10 Most antigens and vaccines trigger B- and T-cell responses, such that there is no rationale in opposing vaccines favoring antibody production (“humoral immunity”) and T-cell responses (“cellular immunity”). In addition, CD4+ T cells are required for most antibody responses, whereas antibodies exert significant influences on T-cell responses to intracellular pathogens.11

# What Are the Main Effectors of Vaccine Responses?

The nature of the vaccine exerts a direct influence on the type of immune effectors that are elicited and that mediate protec- tive efficacy ([Table 2.2](#_bookmark2)).

Capsular polysaccharides (PSs) elicit B-cell responses in what is classically reported as a T-independent manner.12 The conjugation of bacterial PS to a protein carrier (e.g., glyco- conjugate vaccines) provides foreign peptide antigens that are presented to the immune system and, thus, recruit

**BOX 2.1** Main Immunological Definitions

**ADJUVANT**

Agents that increase the stimulation of the immune system by enhancing antigen presentation (depot formulation, delivery systems) and/or by providing costimulation signals (immunomodulators). Aluminum salts are most often used in today’s vaccines.

**AFFINITY, AVIDITY**

Antibody affinity refers to the tendency of an antibody to bind to a specific epitope at the surface of an antigen; that is, to the strength of the interaction. Avidity is the sum of the epitope- specific affinities for a given antigen. It directly relates to its function.

**AFFINITY MATURATION**

Processes through which antigen-specific B cells undergo somatic hypermutation and affinity-based selection, resulting in B cells that produce antibodies with increased affinity over germline antibodies.

**ANTIBODIES**

Proteins of the immunoglobulin family, present on the surface of B lymphocytes, secreted in response to stimulation, that neutralize antigens by binding specifically to their surface.

**ANTIGEN-PRESENTING CELLS**

Cells that capture antigens by endocytosis or phagocytosis, process them into small peptides, display them at their surface through major histocompatibility complex (MHC) molecules, and provide costimulation signals that act synergistically to activate antigen-specific T cells. Antigen-presenting cells include B cells, macrophages, and dendritic cells, although only dendritic cells are capable of activating naïve T cells.

**B LYMPHOCYTES**

Cells that originate in the bone marrow, mature in secondary lymphoid tissues, become activated in the spleen/nodes when their surface immunoglobulins bind to an antigen, and differentiate into antibody secreting cells (plasma cells) or memory B cells.

**CARRIER PROTEIN**

A protein that is used as a template to which polysaccharide moieties are chemically conjugated to generate glycoconjugate vaccines. It is believed that carrier proteins provide antigenic epitopes for recognition by CD4+ T-helper cells, in particular follicular T-helper cells.

**CD4+ T-HELPER 1 LYMPHOCYTES**

CD4+ T cells that on activation differentiate into cells that mainly secrete interleukin (IL)-2, interferon (IFN)-γ, and tumor necrosis factor (TNF)-β, exerting direct antimicrobial functions (viruses), and essentially providing support to cytotoxic T cells and macrophages.

**CD4+ T-HELPER 2 LYMPHOCYTES**

CD4+ T cells that on activation differentiate into cells that mainly secrete IL-4, IL-5, IL-6, IL-10, and IL-13, exerting direct antimicrobial functions (parasites) and essentially providing support to B lymphocytes.

**CD4+ T-HELPER 17 LYMPHOCYTES**

CD4+ T cells that mainly secrete IL-17, IL-21, and IL-22 are implicated in host defense against extracellular bacteria colonizing exposed surfaces (airways, skin, gut).

**2**

**CD8+ T CELLS**

Lymphocytes that specialize in the killing of infected cells, through direct contact or cytokine (IFN-γ, TNF-α) production.

**CENTRAL MEMORY T CELLS**

Memory T cells traffick through the lymph nodes, ready to proliferate and generate a high number of effector cells in response to specific microbial peptides.

**CHEMOKINES**

Small secreted proteins that function as chemoattractants, recruiting cells that express the corresponding chemokine receptors at their surface and thus migrating toward higher concentrations of chemokines.

**COSTIMULATORY MOLECULES**

Molecules that become expressed at the surface antigen- presenting cells on activation and deliver stimulatory signals to other cells, namely T and B cells.

**DENDRITIC CELLS**

Cells that constantly sample their surroundings for pathogens such as viruses and bacteria, detect dangers, and initiate immune responses. Immature patrolling dendritic cells (DCs) have high endocytic activity and a low T-cell activation potential. Contact with a pathogen induces maturation and the expression of certain cell-surface molecules, greatly enhancing their ability to activate T cells.

**EFFECTOR MEMORY T CELLS**

Memory T cells patrol through the body to detect specific microbial peptides and are capable of an immediate cytotoxic function in case of recognition.

**EXTRAFOLLICULAR REACTION**

B-cell differentiation pathways that occur outside of germinal centers in response to protein or polysaccharide antigens. Extrafollicular reaction is rapid, generates B cells that are short-lived (days), and produces low-affinity antibodies without inducing immune memory.

**FOLLICULAR DENDRITIC CELLS**

Stromal cells in the spleen and nodes that on activation express chemokines (notably CXCL13) to attract activated antigen-specific B and T cells and thus nucleate the germinal center reaction.

Follicular DCs provide antiapoptotic signals to germinal center (GC) B cells and support their differentiation into plasma cells or memory B cells.

**FOLLICULAR T-HELPER LYMPHOCYTES**

CD4+ T cells that on activation migrate toward follicular DCs and provide critical help to germinal center B cells, influencing isotype switching, affinity maturation, and differentiation.

**GERMINAL CENTERS**

Dynamic structures that develop in the spleen/nodes in response to an antigenic stimulation and dissolve after a few weeks. GCs contain a monoclonal population of antigen-specific B cells that proliferate and differentiate through the support provided by follicular DCs and T-helper cells. Immunoglobulin class-switch recombination, affinity maturation, B-cell selection, and differentiation into plasma cells or memory B cells essentially occur in GCs.

*Continued on following page*

**BOX 2.1** Main Immunological Definitions (Continued)

**ISOTYPE SWITCHING**

Switch of immunoglobulin (Ig) expression and production from IgM to IgG, IgA, or IgE that occurs during B-cell differentiation through DNA recombination.

**MARGINAL ZONE**

The area between the red pulp and the white pulp of the spleen. Its major role is to trap particulate antigens from the circulation and present them to lymphocytes.

**PATTERN RECOGNITION RECEPTORS**

Germline-encoded receptors sensing the presence of infection via the recognition of conserved microbial pathogen- associated molecular patterns and triggering innate immune responses.

**REGULATORY T CELLS**

T cells that on activation differentiate into cells that express specific cytokines (IL-10, transforming growth factor [TGF]-β/ surface markers) and act to suppress activation of the immune system through various mechanisms, maintaining immune homeostasis and tolerance to self-antigens.

**RESIDENT MEMORY T CELLS**

Effector memory T cells residing in specific tissues (lungs, gut, skin) and conferring an immediate-early line of defense against viral and bacterial pathogens.

**SOMATIC HYPERMUTATION**

A process that introduces random mutation in the variable region of the B-cell receptor (i.e., immunoglobulin) locus at an extremely

high rate during B-cell proliferation. This mechanism occurs through the influence of the activation-induced cytidine deaminase enzyme and generates antibody diversification.

**T LYMPHOCYTES**

Cells that originate in the thymus, mature in the periphery, become activated in the spleen/nodes if their T-cell receptors bind to an antigen presented by an MHC molecule and they receive additional costimulation signals driving them to acquire killing (mainly CD8+ T cells) or supporting (mainly CD4+ T cells) functions.

**T-INDEPENDENT B-CELL RESPONSES**

Differentiation pathway of B cells, mainly elicited by polysaccharides, that takes place in the marginal zone and extrafollicular areas of the spleen/nodes. Its hallmarks are to be rapid (days), while eliciting the transient (months) production of antibodies of low affinity without inducing immune memory.

**T-DEPENDENT B-CELL RESPONSES**

Differentiation pathway of B cells elicited by protein antigens that recruit T and B cells into GCs of the spleen/nodes. Its hallmarks are to be slow (weeks), while eliciting long-lasting (years) production of antibodies of high affinity and immune memory.

**TOLL-LIKE RECEPTORS**

A family of 10 receptors (TLR1 to TLR10), present at the surface of many immune cells, that recognize pathogens through conserved microbial patterns and activate innate immunity when detecting danger.

|  |
| --- |
| **TABLE 2.1** Effector Mechanisms Triggered by Vaccines |
| * Antibodies prevent or reduce infections by clearing extracellular pathogens through:   + Binding to the enzymatic active sites of toxins or preventing their diffusion   + Neutralizing viral replication (e.g., preventing viral binding and entry into cells)   + Promoting opsonophagocytosis of extracellular bacteria (i.e., enhancing their clearance by macrophages and neutrophils)   + Activating the complement cascade |
| * CD8+ T cells do not prevent infection but reduce, control, and clear intracellular pathogens by:   + Directly killing infected cells (release of perforin, granzyme, etc.)   + Indirectly killing infected cells through antimicrobial cytokine release |
| * CD4+ T cells do not prevent infection but participate in the reduction, control, and clearance of extracellular and intracellular pathogens by their homing and cytokine-production capacities. Their main subsets include:   + Follicular T-helper (Tfh) cells producing mainly interleukin (IL)-21 and providing B-cell help   + T-helper 1 (Th1) effector cells producing interferon (IFN)-γ, tumor necrosis factor (TNF)-α/TNF-β, IL-2, and mainly involved in protection against intracellular pathogens (viruses, *Mycobacterium tuberculosis*)   + Th2 effector cells producing IL-4, IL-5, IL-13, and responding to extracellular pathogens (bacteria and helminths)   + Th9 effector cells producing IL-9 and also responding to extracellular pathogens   + Th17 effector cells producing IL-17, IL-22, and IL-26 and contributing to mucosal defense (*Streptococcus pneumoniae, Bordetella pertussis*, *Mycobacterium tuberculosis*) |

antigen-specific CD4+ Tfh cells in what is referred to as a T-dependent antibody response.13,14 A hallmark of T-dependent responses, which are also elicited by toxoid, protein, inacti- vated, or live attenuated viral vaccines (see [Table 2.2](#_bookmark2)), is to induce higher-affinity antibodies and immune memory. In addition, live attenuated vaccines usually generate CD8+ cyto- toxic T cells. The use of live vaccines/vectors or of specific novel delivery systems seems necessary for the induction of strong CD8+ T-cell responses. Most current vaccines mediate their protective efficacy through the induction of vaccine antibod- ies, whereas vaccine-induced CD4+ T cells contribute to mac-

rophage activation and control of *Mycobacterium tuberculosis*15 and prevent varicella-zoster reactivation. In addition, CD8+ T cells are also elicited*.*16

The induction of antigen-specific immune effectors (and/ or of immune memory cells) by an immunization process does not imply that these antibodies, cells, or cytokines rep- resent surrogates—or even correlates—of vaccine efficacy. This requires the formal demonstration that vaccine-mediated pro- tection is dependent—in a vaccinated person—on the pres- ence of a given marker such as an antibody titer or a number of antigen-specific cells above a given threshold.17,18

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TABLE 2.2** Correlates of Vaccine-Induced Immunity | | | | | |
| **Vaccines** | **Vaccine Type** | **Serum IgG** | **Mucosal IgG** | **Mucosal IgA** | **T Cells** |
| Cholera | Killed | ++ | + |  |  |
| Cholera | Live, oral | + | ++ |  |  |
| Diphtheria toxoid | Toxoid | ++ | (+) |  |  |
| Hepatitis A | Killed | +++ |  |  |  |
| Hepatitis B (HBsAg) | Protein | ++ |  |  |  |
| Hib PS | PS | ++ | (+) |  |  |
| Hib glycoconjugates | PS-protein | +++ | ++ |  |  |
| Influenza | Killed, subunit | ++ | (+) |  |  |
| Influenza intranasal | Live attenuated | ++ | + | + | + (CD8+) |
| Japanese encephalitis | Killed | ++ |  |  |  |
| Measles | Live attenuated | +++ |  |  | + (CD8+) |
| Meningococcal PS | PS | ++ | (+) |  |  |
| Meningococcal conjugates | PS-protein | +++ | ++ |  |  |
| Meningococcal group B | Proteins |  |  |  |  |
| Mumps | Live attenuated | ++ |  |  |  |
| Papillomavirus (human) | VLPs | +++ | ++ |  |  |
| Pertussis, whole cell | Killed | ++ |  |  | +? (CD4+) |
| Pertussis, acellular | Proteins | ++ |  |  | +? (CD4+) |
| Pneumococcal PS | PS | ++ | (+) |  |  |
| Pneumococcal conjugates | PS-protein | +++ | ++ |  |  |
| Polio Sabin | Live attenuated | ++ | ++ | ++ |  |
| Polio Salk | Killed | ++ | + |  |  |
| Rabies | Killed | ++ |  |  |  |
| Rotavirus | VLPs | (+) | (+) | ++ |  |
| Rubella | Live attenuated | +++ |  |  |  |
| Tetanus toxoid | Toxoid | +++ |  |  |  |
| Tuberculosis (BCG) | Live mycobacteria |  |  |  | ++ (CD4+) |
| Typhoid PS | PS | + | (+) |  |  |
| Varicella (chickenpox) | Live attenuated | ++ |  |  | +? (CD4+) |
| Varicella (zoster) | Live attenuated |  |  |  | ++ (CD4+) |
| Yellow fever | Live attenuated | +++ |  |  |  |
| BCG, bacille Calmette-Guérin; Hib, *Haemophilus influenzae* type b; PS, polysaccharide; VLP, virus-like particle. Note: This table may not be exhaustive and includes only currently licensed vaccines. | | | | | |

**2**

Antigen-specific antibodies have been formally demon- strated as conferring vaccine-induced protection against many diseases19 (see [Table 2.2](#_bookmark2)). Passive protection may result from the physiological transfer of maternal antibodies (e.g., tetanus) or the passive administration of immunoglobulins or vaccine- induced hyperimmune serum (e.g., measles, hepatitis, vari- cella). Such antibodies may neutralize toxins in the periphery, at their site of production in an infected wound (tetanus), or in the throat (diphtheria). They may reduce binding or adhe- sion to susceptible cells or receptors and limit viral replication (e.g., polio) or reduce bacterial colonization (glycoconjugate vaccines against encapsulated bacteria) if present at suffi- ciently high titers on mucosal surfaces.20 The neutralization of pathogens at mucosal surfaces is mainly achieved by the transudation of vaccine-induced serum immunoglobulin (Ig) G antibodies. Neutralization requires serum IgG antibody

concentrations to be of sufficient affinity and abundance to result in “protective” antibody titers in saliva or mucosal secre- tions. As a rule, such responses are not elicited by PS bacterial vaccines but achieved by glycoconjugate vaccines, which may prevent nasopharyngeal colonization or nonbacteremic pneu- monia21 in addition to invasive diseases.

Under most circumstances, inactivated vaccines do not elicit sufficiently high and sustained antibody titers on mucosal surfaces to prevent local infection. It is only after having infected mucosal surfaces that pathogens encounter vaccine- induced IgG serum antibodies that neutralize viruses, opso- nize bacteria, activate the complement cascade (see [Table 2.1](#_bookmark1)), and limit their multiplication and spread, preventing tissue damage and, thus, clinical disease. That vaccines fail to induce sterilizing immunity is not an obstacle to successful disease control, although it represents a significant challenge for

the development of specific vaccines against chronic viral infection.

Current vaccines mostly mediate protection through the induction of highly specific IgG serum antibodies (see [Table](#_bookmark2) [2.2](#_bookmark2)). Live oral or nasal vaccines, such as rotavirus, oral polio, nasal influenza, or cholera vaccines, induce serum IgA and secretory IgA, which also help limit viral shedding on mucosal surfaces.

Under certain circumstances, however, passive antibody- mediated immunity is inefficient (tuberculosis). There is con- clusive evidence that T cells are the main effectors of BCG, even though specific T-cell frequency and cytokine expression profiles do not correlate with protection in BCG-immunized infants,15,22 or in zoster immunized adults.23,24 However, there is indirect evidence that vaccine-induced T cells contribute to the protection conferred by other vaccines. CD4+ T cells seem to support the persistence of protection against clinical pertus- sis in children primed in infancy, after vaccine-induced anti- bodies have waned,25–28 and may contribute to the longer vaccine efficacy of whole-cell pertussis vaccines.29–31 Another example is that of measles immunization in 6-month-old infants in whom antibody responses largely are not initiated because of immune immaturity and/or the residual presence of inhibitory maternal antibodies, but significant interferon (IFN)-γ–producing CD4+ T cells are generated.32,33 The infants remain susceptible to measles infection but are protected against severe disease and death, presumably because of the viral clearance capacity of their vaccine-induced T-cell effec- tors. Thus, prevention of infection may be achieved only by vaccine-induced antibodies, whereas disease attenuation and protection against complications may be supported by T cells, even in the absence of specific antibodies. The understanding of vaccine immunology requires appraising how B- and T-cell responses are elicited, supported, maintained, and/or reacti- vated by vaccine antigens.

# FROM INNATE TO ADAPTIVE IMMUNITY ACTIVATION: THE FIRST STEPS

**AFTER IMMUNIZATION**

Novel adjuvants essentially enhance vaccine responses by modulating innate immunity, which shapes adaptive responses.34–38 Indeed, the induction of antigen-specific B- and T-cell responses requires their activation in the draining lymph nodes by specific antigen-presenting cells (APCs), essentially dendritic cells (DCs) that must be recruited into the reaction. Immature DCs patrol throughout the body. When exposed to pathogens in the tissues or at the site of injection, they undergo brisk maturation, modulate specific surface receptors, and migrate toward secondary lymph nodes, where the induction of T- and B-cell responses occurs. The central role for mature DCs in the induction of vaccine responses reflects their unique capacity to provide antigen-specific, costimulation signals to T cells; these “danger signals” are required to activate naïve T cells.39 The very first requirement to elicit vaccine responses is to provide sufficient “danger signals” through vaccine antigens and/or adjuvants ([Fig. 2.1](#_bookmark3)) to trigger an inflammatory reaction that is mediated by cells of the innate immune system.34–37

DCs, monocytes, and neutrophils express sets of receptors

directed against evolutionarily conserved pathogen patterns that are not contained in self-antigens and are readily identi- fied as “danger.”40 Through these pattern-recognition recep- tors, among which Toll-like receptors fulfill an essential role ([Table 2.3](#_bookmark4)),40 these host cells sense the potential danger when they encounter a pathogen and become activated ([Fig. 2.2](#_bookmark5)). They modulate the expression of their surface molecules and

produce proinflammatory cytokines and chemokines,34–37 which result in the extravasation and attraction of monocytes, granulocytes, and natural killer cells and the generation of an inflammatory microenvironment (see [Fig. 2.1](#_bookmark3)) in which monocytes differentiate into macrophages and immature DCs become activated.38 This activation modifies the expression of homing receptors at their surface and triggers DC migration toward the draining lymph nodes (see [Fig. 2.2](#_bookmark5)). In the absence of danger signals, DCs remain immature: On contact with naïve T cells, T cells do not differentiate into immune effectors but into regulatory CD4+ T cells that maintain immune tolerance.10

Live viral vaccines most efficiently trigger the activation of the innate immune system through multiple pathogen- associated signals (such as viral RNA), allowing their recognition by pattern-recognition receptors (see [Table 2.3](#_bookmark4)).41 Following injection, viral particles rapidly disseminate throughout the vascular network and reach their target tissues. This pattern is very similar to that occurring after a natural infection, including the initial mucosal replication stage for vaccines administered through the nasal and oral routes. DCs are activated at multiple sites, migrate toward the correspond- ing draining lymph nodes, and launch multiple foci of T- and B-cell activation. This sequence provides a second explanation of the generally higher immunogenicity of live versus “nonlive” vaccines ([Table 2.4](#_bookmark6)).42 Another consequence of this early dif- fusion pattern is that the site and route of injection of live viral vaccines are of minor importance; for example, the immuno- genicity and reactogenicity of measles vaccine is similar fol- lowing intramuscular or subcutaneous injection,43 and measles vaccine may be administered by aerosol. Live bacterial vac- cines, such as BCG, multiply at the site of injection, where they generate a prolonged inflammatory reaction, but also at a distance, with the preponderance for local draining lymph nodes.

Nonlive vaccines, whether containing only proteins, PS,

glycoconjugates, or inactivated microorganisms (see [Table](#_bookmark2) [2.2](#_bookmark2)), may still contain pathogen-recognition patterns. In the absence of microbial replication, however, vaccine-induced activation remains more limited, in both time and space. Nonlive vaccines essentially activate innate responses at their site of injection (see [Fig. 2.1](#_bookmark3)). Their site and route of admin- istration are, thus, more important. The high number of DCs in the dermis allows a marked reduction (e.g., 10-fold) of the antigen dose with intradermal immunization. This advantage of the dermal DC concentration is applied to the prevention of rabies in many countries and could prove useful against additional targets as novel microneedle and needle-free devices become available for intradermal administration.44 Patrolling DCs are also numerous in well-vascularized muscles, which is the preferred route of injection for nonlive vaccines. They are fewer in adipose tissues, such that subcutaneous injections may be less effective than intramuscular injections under conditions of limited immunogenicity, as demonstrated for adult immunization against hepatitis B.45 Despite many efforts, immunization through the mucosal route remains limited to a few live vaccines. The extreme difficulty in produc- ing nonlive mucosal vaccines reflects the need to overcome a large number of physical, immunological, and chemical bar- riers, which requires the use of live vaccines or strong adju- vants. This fact is not trivial, as unfortunately illustrated by the association of a novel adjuvanted inactivated intranasal influ- enza vaccine with Bell palsy.46

Following their activation, DCs migrate toward the local







draining lymph nodes, for example, the axillary and inguinal area following deltoid and quadriceps injection, respectively. That primary immune responses to nonlive vaccines are essentially focal and likely contribute to the fact that the

**2**



1

**Figure 2.1.** Initiation of a vaccine response. Following injection *(1)*, the pathogen-associated patterns contained in vaccine antigens attract dendritic cells, monocytes, and neutrophils that patrol throughout the body *(2)*. Elicitation of sufficient “danger signals” by the vaccine antigens (Ag)/adjuvants (Adj) activates monocytes and dendritic cells *(3)*; the activation changes their surface receptors and induces their migration along lymphatic vessels *(4)*, to the draining lymph nodes *(5)* where the activation of T and B lymphocytes will take place.



Muscular tissue

Ag/Adj

Ag

Ag/Adj

Ag

Ag

Ag

Ag

Ag

Ag

2

Ag

3

Ag

Ag

Lymph node

Ag

Ag

5






4

|  |  |  |
| --- | --- | --- |
| **TABLE 2.3** Recognition of Vaccine Determinants by Human Pattern-Recognition Receptors | | |
| **Receptors** | **Ligands** | **Demonstrated Ligands in Vaccines** |
| TLR1 | Certain bacterial lipoproteins |  |
| TLR2 | Peptidoglycan, lipoproteins, glycolipids, lipopolysaccharides | BCG, Hib-OMP, pneumococcal PS |
| TLR3 | Viral double-stranded RNA | Poly I:C (in clinical trial as adjuvant) |
| TLR4 | Bacterial lipopolysaccharides | BCG, pneumococcal PS, HPV-VLPs, AS02, and AS04 adjuvants |
| TLR5 | Bacterial flagellins | Flagellin (in clinical trial as adjuvant) |
| TLR6 | Lipoteichoic acid, lipopeptides |  |
| TLR7 | Single-stranded RNA | Yellow fever, live attenuated influenza, whole-cell influenza, TLR7 agonists (in clinical trial as adjuvants) |
| TLR8 | Single-stranded RNA | Yellow fever |
| TLR9 | Unmethylated CpG oligonucleotides | Yellow fever, TLR9 agonists (in clinical trial as adjuvants) |
| TLR10 | Unknown |  |
| NALP3 | Multiple | Alum |
| NOD1, NOD2 | Peptidoglycans | Pneumococcal PS |
| BCG, bacille Calmette-Guérin; CpG, cytosine phosphate guanine; Hib, *Haemophilus influenzae* type b; HPV, human papillomavirus; NALP, Natch domain, Leucine-rich repeat, and PYD-containing protein; NOD, nonobese diabetic; OMP, outer membrane protein; PS, polysaccharide; TLR, Toll-like receptor; VLP, virus-like particle. | | |

simultaneous administration of several distinct vaccines may take place without immune interference if vaccines are admin- istered at distant sites in different limbs draining into distinct lymph node areas. Most nonlive vaccines require their formu- lation with specific adjuvants to induce danger signals and

trigger a sufficient activation of the innate system. The under- standing of the mode of action of current and novel adjuvants markedly increased during the last few years, with the long- used aluminum salts revealing some of their secrets.47 Although the adjuvants currently in use do not trigger the degree of

Spleen/lymph nodes Blood Bone marrow



Germinal centers

Ag

Ag

6

IgG

IgA

Ag

Ag

Th

5

Tfh FDC

B

1

8

7

IgG

2

IgG+

IgG

IgA

3

IgA+

4

**Figure 2.2.** Extrafollicular and germinal center responses to protein antigens. In response to a protein antigen reaching lymph nodes or spleen, B cells capable of binding to this antigen with their surface immunoglobulins *(1)* undergo brisk activation. In an extrafollicular reaction *(2),* B cells rapidly differentiate in plasma cells *(3)* that produce low-affinity antibodies (of the immunoglobulin [Ig] M ± IgG/IgA isotypes) that appear at low levels in the serum within a few days after immunization *(4).* Antigen-specific T-helper (Th) cells *(5)* that have been activated by antigen- bearing dendritic cells (DCs) trigger some antigen-specific B cells to migrate toward follicular dendritic cells (FDCs) *(6),* initiating the germinal center (GC) reaction. In GCs, B cells receive additional signals from follicular T cells (Tfh) and undergo massive clonal proliferation; switch from IgM toward IgG, IgA, or IgE; undergo affinity maturation *(7)*; and differentiate into plasma cells secreting large amounts of antigen-specific anti- bodies *(8).* At the end of the GC reaction, a few plasma cells exit nodes/spleen and migrate to survival niches mostly located in the bone marrow, where they survive through signals provided by supporting stromal cells.

|  |  |
| --- | --- |
| **TABLE 2.4** Determinants of Primary Vaccine Antibody Responses in Healthy People | |
| **Determinants** | **Mechanisms (Presumed)** |
| **Vaccine Type** |  |
| Live vs inactivated | Higher intensity of innate responses through the synergistic activation of several PRRs, higher antigen content following replication, and more prolonged antigen persistence generally result in higher Ab responses to live than to inactivated vaccines. |
| Protein vs polysaccharide | Recruitment of T-cell help and induction of GCs (i.e., memory induction) results in higher and more prolonged Ab responses to protein or glycoconjugate than to PS vaccines. |
| Adjuvants | Modulation of antigen delivery and persistence (depot or slow-release formulations) and/or enhancement of Tfh responses (immunomodulator) may support or limit Ab responses. |
| **Antigen Nature** |  |
| Polysaccharide antigens | Failure to induce GCs limits immunogenicity. |
| Protein antigens | Inclusion of epitopes readily recognized by B cells (B-cell repertoire), inclusion of epitopes readily recognized by Tfh, elicitation of efficient follicular T-cell help, and the capacity of antigen to associate/persist in association with FDCs result in higher Ab responses. |
| Antigen dose | As a rule, higher Ag doses increase the availability of Ag for B-/T-cell binding and activation and for association with FDCs. |
| **Vaccine Schedule** |  |
| Interval between doses | A 3-week minimal interval between primary doses avoids competition between successive waves of primary responses. |
| Genetic determinants | The capacity of Ag epitopes to associate with a large panel of MHC molecules increases the likelihood of responses in the population. MHC restriction may limit T-cell responses. Gene polymorphisms in molecules critical for B- and  T-cell activation/differentiation are likely to affect Ab responses. |
| Environmental factors | Mostly unidentified |
| Age at immunization | Early life immune immaturity or age-associated immune senescence |
| Ab, antibody; Ag, antigen; FDC, follicular dendritic cell; GC, germinal center; MHC, major histocompatibility complex; PRR, pattern-recognition response; PS, polysaccharide; Tfh, follicular T-helper cells. | |

innate immune activation that is elicited by live vaccines, progress is being made: a single dose of the AS03-adjuvanted influenza H1N1/09 vaccine in healthy children elicited anti- body responses similar to those observed in convalescent chil- dren48 and formulating the varicella-zoster-virus IgE protein into the novel AS01b adjuvant system conferred unprece- dented vaccine efficacy in the elderly.24

# VACCINE ANTIBODY RESPONSES

**How Are Primary Antibody Responses Elicited?**

B cells are essentially activated in the lymph nodes draining the injection site. Vaccine antigens reaching the subcapsular sinus by free-fluid diffusion are taken up by specific subcap- sular sinus macrophages and translocated into the B-cell zone. The B cells equipped with surface B-cell receptors49 capable of binding to the vaccine antigens are activated and migrate to the interface between the B-cell (follicle) and the T-cell zones. There, B cells engage T cells and initiate their proliferation. The cumulative amount of costimulation signals received by B cells determines their fate.50 Protein antigens (which are taken up and displayed as small peptides on the surface of APCs) activate Tfh cells. This induces a highly efficient B-cell differentiation pathway, through specific structures (germinal centers [GCs]) in which antigen-specific B cells proliferate and differentiate into antibody-secreting plasma cells or memory B cells.51 Polysaccharide antigens that fail to recruit Tfh cells into the response do not trigger GCs, such that they elicit only short-lived plasma cells resulting in weaker and less durable antibody responses with no immune memory.

## T-Dependent Responses to Protein Antigens

**The Extrafollicular Reaction.** Naïve B cells generated in the bone marrow (BM) reside in lymph nodes until they encoun- ter a protein antigen to which their specific surface IgM recep- tor binds. Antigen binding initiates B-cell activation and triggers the upregulation of CCR7, a chemokine receptor that drives antigen-specific B cells toward the outer T-cell zone of lymph nodes.52 At this location, vaccine antigen-specific B cells are exposed to recently (<24 hours) activated DCs and T cells that have upregulated specific surface molecules and, thus, provide B-cell activating signals. This T-cell help rapidly drives B-cell differentiation into Ig-secreting plasma cells that produce low-affinity germline antibodies, in what is called the extrafollicular reaction (see [Figs. 2.2](#_bookmark5) and [2.3](#_bookmark7)).53

Ig class-switch recombination from IgM toward IgG, IgA, or IgE occurs during this differentiation of B cells, through the upregulation of the activation-induced deaminase enzyme. Both CD4+ Th1 and Th2 cells exert essential helper functions during the extrafollicular differentiation pathway, and the engagement of their CD40L molecules with CD40 on B cells may skew class-switch recombination into particular Ig classes and subclasses. In rodents, IFN-γ–producing Th1 T cells promote a switch toward IgG2a, whereas Th2 cells essentially support the generation of IgG1 and IgE (via IL-4) and IgG2b and IgG3 (via transforming growth factor [TGF]-β).54 The situ- ation is less clear-cut in humans, where IgG1 antibodies fre- quently predominate regardless of the polarization of T-cell help. The extrafollicular reaction is rapid, and IgM and low- level IgG antibodies appear in the blood a few days after primary immunization (see [Figs. 2.2](#_bookmark5) and [2.3](#_bookmark7)). These antibod- ies are of germline affinity, as there is no hypermutation or selection process during the extrafollicular reaction. This extra- follicular reaction is short-lived, as most cells die by apoptosis within a few days. Consequently, its role in vaccine efficacy is limited to a few months.

**The Germinal Center Reaction.** Antigen-specific B cells that receive sufficient help from antigen-specific activated Tfh cells proliferate in specialized structures, the GCs, in which they differentiate into plasma cells or memory B cells.50,55 The induction of GCs is initiated as a few antigen-specific activated B cells upregulate their expression of CXCR5 and migrate toward B-cell follicles, where they are attracted by CXCL13- expressing follicular DCs (FDCs). The FDCs fulfill an essential role in B-cell responses: they attract antigen-specific B and Tfh cells and capture/retain antigen for extended periods. B cells attracted by antigen-bearing FDCs become the founders of GCs (see [Fig. 2.2](#_bookmark5)). Receiving additional activation and survival signals from the FDCs and Tfh cells,56,57 notably through IL-21,58 B cells undergo massive clonal proliferation—such that each GC is constituted by the progeny of a single antigen- specific B cell. This intense proliferation is associated with two major events: Ig class-switch recombination from IgM toward IgG, IgA, or IgE, and maturation of the affinity of B cells for their specific antigen. This process results in the higher pro- duction of antibodies with a higher antigen-binding capacity (see [Fig. 2.3](#_bookmark7)).

The maturation of B-cell affinity results from an extensive

**2**

somatic hypermutation process within the variable-region segments of Ig genes.50 In a small minority of B cells, the introduction of mutations in their Ig genes increases the affin- ity of their surface IgG for antigen. This enables these B cells to efficiently compete for binding to the small amounts of vaccine antigens that are associated with the surface of FDCs (see [Fig. 2.2](#_bookmark5)). B cells process these vaccine antigens into small peptides that they display at their surface through major his- tocompatibility complex (MHC) class II molecules. MHC- peptide complexes thus become available for binding by the specific subset of CD4+ Tfh cells.56,57 These Tfh cells, which express CXCR5, migrate toward CXCL13-expressing FDCs. Differing from Th1 and Th2 cells by their chemokine recep- tors, transcription factors, surface markers, and interleu- kins,56,57 they are uniquely equipped to provide efficient B-cell help through a series of costimulation molecules, including CD40L, ICOS (inducible T-cell costimulator), the IL-10 B-cell growth factor, and IL-21.56,57 The cellular interactions between antigen-specific GC B cells, antigen-bearing FDCs, and antigen-specific Tfh cells (see [Fig. 2.2](#_bookmark5)) result in the prolifera- tion, survival, and selection of B cells that have the highest possible antigen-specific affinity. They also provide the signals required for the subsequent differentiation of GC B cells toward plasma cells secreting large amounts of specific anti- bodies or toward memory B cells. Tfh cells have thus been identified a major determinant of adult and early life B-cell vaccine responses.5–7

The development of this GC reaction requires a couple of

weeks, such that hypermutated IgG antibodies to protein vaccine antigens first appear in the blood 10 to 14 days after priming (see [Fig. 2.3](#_bookmark7)).59 Feedback mechanisms terminate GC reactions within 3 to 6 weeks, a period during which a large number of antigen-specific plasma cells will have been gener- ated. It is the magnitude of GC responses, that is, the quality of DC, B-cell, Tfh-cell, and FDC interactions, which controls the intensity of B-cell differentiation into plasma cells and thus the peak of IgG vaccine antibody reached within 4 to 6 weeks after primary immunization (see [Fig. 2.3](#_bookmark7)).

## T-Independent Responses to Polysaccharide Antigens

Bacterial (*Streptococcus pneumoniae, Neisseria meningitidis, Hae- mophilus influenzae, Salmonella typhi*) PS antigens released from the injection site reach the marginal zone of the spleen/nodes, an area that is equipped by macrophages exhibiting a unique set of scavenger receptors through the bloodstream. There, PS

**Figure 2.3.** Correlation of antibody titers to the various phases of the vaccine response. The initial antigen exposure elicits an extrafollicular response *(1)* that results in the rapid appearance of low IgG antibody titers. As B cells proliferate in germinal centers and differentiate into plasma cells, IgG antibody titers increase up to a peak value *(2),* usually reached 4 weeks after immunization. The short life span of these plasma cells results in a rapid decline of antibody titers *(3),* which eventually return to baseline levels *(4).* In secondary immune responses, booster exposure to antigen reactivates immune memory and results in a rapid (<7 days) increase *(5)* of IgG antibody titer. Short-lived plasma cells maintain peak antibody levels *(6)* during a few weeks—after which serum antibody titers decline initially with the same rapid kinetics as following primary immu- nization *(7)*. Long-lived plasma cells that have reached survival niches in the bone marrow continue to produce antigen-specific antibodies, which then decline with slower kinetics *(8)*. Note: This generic pattern may not apply to live vaccines triggering long-term IgG antibodies for extended periods.



Booster antigen exposure

6mo

Time

Time

Primary antigen exposure

0 7d 30d

10d 30d

0

4

3

1

2

5

8

7




6

Secondary immune response

Primary immune response

Antibody titer (IgG, log10)

Spleen/lymph nodes Blood



PS

1

B

2

IgM+

IgM

3

IgG+

IgA+

5

4

IgG

+

IgA+

**Figure 2.4.** Extrafollicular B-cell responses to polysaccharide antigens. B cells use their specific immunoglobulin surface receptors *(1)* to bind to the repetitive structures of polysaccharides reaching the marginal zone of spleen/nodes. In the absence of antigen-specific T-cell help, B cells are activated, proliferate *(2),* and differentiate in plasma cells *(3)* without undergoing affinity maturation in germinal centers. These plasma cells migrate toward the red pulp of the spleen *(4)*, where they survive for a few weeks/months, secreting low levels of low-affinity immunoglobulin (Ig) M, IgG, or IgA antibodies *(5).*

bind to marginal zone B cells, and their repetitive structure crosslinks the Ig receptors on the B-cell surface.53 This activates extrafollicular marginal zone B cells ([Fig. 2.4](#_bookmark8)).53 During the week following immunization, B cells differentiate into plasma cells, undergo some degree of isotype switching from

IgM to IgG/IgA, and—in rodents—rapidly produce essentially nonmutated, low-affinity, germline antibodies. Thus, PS vaccines are generally known as triggering T-independent responses characterized by the induction of moderate titers of low-affinity antibodies and the absence of immune memory.

In humans, PS immunization generates the production of intermediate-affinity IgG antibodies bearing some somatic mutations in their variable regions.60,61 One hypothesis is that PS immunization activates “memory” B cells that have been previously primed by cross-reacting PS bacterial antigens somehow linked to protein moieties—and thus eliciting GC responses.62 An alternative possibility is that the IgM+, IgD+, CD27+ memory B cells that appear in the blood in response to PS immunization may be recirculating splenic marginal zone B cells.63 This hypothesis is concordant with the fact that bacterial PS vaccines are poorly immunogenic in young chil- dren, that is, before the maturation of the splenic marginal zone.64,65

After their differentiation in the extrafollicular pathway, PS-specific plasma cells move toward the red pulp of the spleen (see [Fig. 2.4](#_bookmark8)) where they persist for some time, before their death by apoptosis and the waning of corresponding antibody responses after a few months. As PS antigens do not induce GCs, bona fide memory B cells are not elicited. Con- sequently, subsequent reexposure to the same PS results in a repeated primary response that follows the same kinetics in previously primed as in a naïve individual.66 Revaccina- tion with certain bacterial PS may even induce lower anti- body responses than the first immunization, a phenomenon referred to as hyporesponsiveness,67–69 which is increasingly reported70–73 and where the molecular and cellular mecha- nisms include vaccine-induced B cell depletion by apopto- sis.74,75 This phenomenon is time-limited, such that if sufficient time elapses before the administration of a PS vaccine, the B-cell pool would be replenished.

**What Are the Determinants of Primary Vaccine Antibody Responses?** Numerous determinants modulate the intensity of vaccine-induced GCs and, thus, of peak antibody responses ([Table 2.5](#_bookmark9)). The main determinants are the nature of the vaccine antigen and its intrinsic immunogenicity. For example, tetanus toxoid is intrinsically a stronger immunogen than diphtheria toxoid, which becomes more apparent in the face of more limited immunocompetence, such as in preterm infants.76 Whether this difference reflects a higher capacity of tetanus toxoid to provide antigenic epitopes that bind naïve B cells, the ability to generate cognate Tfh-cell help for B cells, and/or to their association with FDCs is unknown.

The markedly different outcomes of immunization with plain bacterial PS and with protein-conjugated glycoconju- gates67 highlight the differences between the extrafollicular

and the GC reactions. It is only when capsular PS are conju- gated to a protein carrier driving effective Tfh differentiation that PS-specific B cells are driven toward GC responses, receive optimal cognate help from carrier-specific Tfh cells, and differentiate into higher-affinity antibody-producing cells, longer-lived plasma cells, and/or memory B cells. Protein anti- gens exhibit markedly distinct carrier properties—regardless of their capacity to induce B- and Th-cell responses.77,78 That these differences may reflect differences in Tfh induction is a likely hypothesis.79,80 The limited number of potent carrier proteins implies that an increasing number of conjugate vac- cines rely on the same carriers (e.g., CRM197, tetanus or diph- theria toxoids), with the risk of limiting anti-PS responses to individual conjugate vaccines (carrier-mediated epitope sup- pression) and resulting in vaccine interference.81,82 This phenomenon may be abrogated by replacing full-length proteins with peptides lacking B-cell epitopes,83 suggesting that carrier-mediated epitope suppression essentially reflects the competition of carrier- and PS-specific B cells for activation/ differentiation signals and factors.

Another determinant of the magnitude of primary

**2**

vaccine antibody responses (see [Table 2.5](#_bookmark9)) is the use of an optimal dose of antigen, which may be determined only experimentally. As a rule, higher doses of nonlive antigens— up to a certain threshold—elicit higher primary antibody responses. This may be particularly useful when immuno- competence is limited, for example, for hepatitis B immuniza- tion of patients undergoing dialysis.84,85 Remarkably, a limiting dose of antigen may restrict primary antibody responses but increase B-cell competition for FDC-associated antigens and, thus, result in a more stringent selection of higher-affinity GC B cells and stronger secondary responses (see subsequent text). Alternatively, adjuvants increasing inflammation at the injection site and, thus, cell recruitment and cell-mediated antigen transport toward lymph nodes, improve antibody responses despite a reduced antigen dose.86 Little is known about factors that support or limit the affinity maturation process87,88 which may be modulated by carrier proteins89 and adjuvants.90–92

The nature of the vaccine directly influences the activation

of innate immunity and, thus, vaccine responses. The stron- gest antibody responses are generally elicited by live vaccines that are “naturally adjuvanted,” because they activate innate reactions, and, thus, support the induction of adaptive immune effectors in addition to providing a replicating antigen. Nonlive vaccines frequently require formulation with

|  |  |
| --- | --- |
| **TABLE 2.5** Determinants of the Duration of Vaccine Antibody Responses in Healthy People | |
| **Determinants** | **Mechanisms (Presumed)** |
| **Vaccine Type** |  |
| Live vs inactivated | Live vaccines generally induce more sustained Ab responses, presumably through Ag persistence within the host. |
| Polysaccharide antigens | Failure to generate Tfh cells and GCs limits the induction of memory responses and of high-affinity long-lived plasma cells. |
| **Vaccine Schedule** |  |
| Interval between primary doses | A minimal interval of 3 weeks between primary doses allows development of successive waves of Ag-specific primary responses without interference. |
| Interval before boosting | A minimal interval of 4 months between priming and boosting allows affinity maturation of memory  B cells and thus higher secondary responses. |
| Age at immunization | Early life immune immaturity and age-associated immunosenescence limit the induction/ persistence of long-lived plasma cells. |
| Environmental factors | Mostly unidentified. |
| Ab, antibody; Ag, antigen; GC, germinal center; Tfh, follicular T-helper cells. | |

adjuvants that enhance and shape vaccine immune responses through a variety of mechanisms.34–37 The potency of the immune system indeed resides in its highly polymorphic nature, enabling sufficient immunological diversity to over- come a high number of diverse pathogens. This diversity impacts vaccine responses.93 Probing how host genetic markers may result in variations of vaccine-induced responses is expected to identify gene polymorphisms that predict the like- lihood of successful or adverse vaccine outcome, whereas epi- genetic studies may help reveal how environmental influences affect innate and adaptive immune responses.93 This work is still in its infancy, but holds great promise, especially when combined with novel systems vaccinology approaches.94–96 Immune competence obviously affects vaccine antibody responses, which are limited at the two extremes of life (see subsequent text), and by the presence of acute or chronic diseases, acute or chronic stress, and a variety of factors affect- ing innate and/or B- and T-cell immunity.

Few nonlive vaccines (e.g., hepatitis A and human papil-

lomavirus [HPV] vaccines) induce high and sustained anti- body responses after a single vaccine dose, even in healthy young adults. Primary immunization schedules therefore usually include at least two doses, optimally repeated at a minimal interval of 3 to 4 weeks (longer intervals enhancing rather than reducing the responses) to generate successive waves of primary B-cell and GC responses. These priming doses may occasionally be combined into a single “double” dose, such as for hepatitis A or B and for HPV immunization.97–101 In any case, vaccine antibodies elicited by primary immunization with nonlive vaccines eventually wane (see [Fig. 2.3](#_bookmark7)).

**What Controls the Persistence of Vaccine Antibody Responses?** Antigen-specific plasma cells elicited in spleen/ nodes after immunization have only a short life span, such that vaccine antibodies rapidly decline during the first few weeks and months after immunization. A fraction of plasma cells that differentiated into GCs, however, acquire the capac- ity to migrate toward long-term survival niches that are mostly located within the BM, from where they may produce vaccine antibodies during extended periods.102–105

Some GC-induced plasma cells are attracted toward the BM compartment by cells that provide the signals required for their long-term survival.50,106–109 In such BM niches, plasma cell survival and antibody production may persist for years. The duration of antibody responses reflects the number and/or quality of long-lived plasma cells generated by immuniza- tion103: In the absence of subsequent antigen exposure, anti- body persistence may be reliably predicted by the antibody titers that are reached 6 to 12 months after immunization, that is, after the end of the short-term plasma cell response (see [Fig. 2.3](#_bookmark7)). This is illustrated by the accuracy of mathematical models predicting the kinetics of anti–hepatitis B surface antigen (HBsAg),110 anti–hepatitis A,111 or anti-HPV112,113 antibodies.

A few determinants of the persistence of vaccine antibody responses (see [Table 2.5](#_bookmark9)) have been identified. The nature of the vaccine has a crucial role: only live attenuated viral vac- cines or virus-like particles induce antibody responses that persist for several decades, if not lifelong, in absence of sub- sequent antigen exposure and reactivation of immune memory. In contrast, the shortest antibody responses are elicited by PS antigens, which fail to trigger Tfh/GC responses and thus do not elicit high-affinity plasma cells capable of reaching the BM survival niches. Antibody persistence may also be modulated by the use of adjuvants.114,115 Vaccine schedules also control antibody magnitude and persistence. Closely spaced (1–2 weeks) primary vaccine doses may be administered when a

rapid induction of protection is desirable, for example, before travel. However, this raises less-persisting responses than when the same number of vaccine doses are given at longer intervals (1–2 months),116,117 reflecting the generation of fewer post-GC B cells capable of long-term survival and thus requiring later boosting. Optimal recall and anamnestic responses require longer intervals of at least 3 to 4 months, with longer intervals associated with generally greater responses (see below).

Age at immunization also modulates vaccine antibody per- sistence, which is shorter at the two extremes of life (see sub- sequent text). Certain conditions may also limit the persistence of vaccine antibody responses because of enhanced catabo- lism (as in HIV)118 or the loss of antibodies in the urinary or digestive tract. The identification of the mechanisms that support or limit the persistence of vaccine antibody responses represents a major challenge.



**What Are the Hallmarks of B-Cell Memory Responses?** Memory B cells are generated during primary responses to T-dependent vaccines.50,119 They persist in the absence of anti- gens but do not produce antibodies (i.e., do not protect), unless reexposure to antigen drives their differentiation into antibody-producing plasma cells. This reactivation is rapid, such that booster responses are characterized by the rapid increase to higher titers of antibodies that have a higher affin- ity for antigens than do antibodies generated during primary responses ([Table 2.6](#_bookmark10)).

Memory B cells are generated in response to T-dependent antigens, during the GC reaction, in parallel to plasma cells ([Fig. 2.5](#_bookmark11)).50,119,120 At their exit of GCs, memory B cells acquire migration properties toward extrafollicular areas of the spleen and nodes. This migration occurs through the bloodstream, in which postimmunization memory B cells are transiently present on their way toward lymphoid organs.

It is essential to understand that memory B cells do not produce antibodies—that is, they do not protect. Their partici- pation in vaccine efficacy requires an antigen-driven reactiva- tion that may occur in response to endemic pathogens, to colonizing or cross-reacting microorganisms (“natural boost- ers”), or to booster immunization. The activation of memory B cells results in their rapid proliferation and differentiation into plasma cells that produce very large amounts of higher- affinity antibodies.120 As the affinity of surface Ig from memory B cells is increased, their requirements for reactivation are lower than for naïve B cells: memory B cells may thus be recalled by lower amounts of antigen and without CD4+ T-cell help, although T-cell help supports a second round of GC responses, further magnifying the level/persistence of antibod- ies.121 Antigen-specific memory cells generated after primary immunization are much more numerous (and better fit) than naïve B cells initially capable of antigen recognition.50,119 Thus, the first hallmark of the memory responses (see [Table 2.6](#_bookmark10)) is

|  |
| --- |
| **TABLE 2.6** Hallmarks of Memory B-Cell Responses |
| Memory B cells:   * Are generated only during T-dependent responses inducing follicular T-helper cells and thus germinal center responses |
| * Are resting cells that do not produce antibodies |
| * Undergo affinity maturation during 4–6 months |
| * Rapidly (days) differentiate into antibody-secreting plasma cells on reexposure to antigen |
| * Differentiate into plasma cells that produce high(er)-affinity antibodies than do primary plasma cells |

Spleen/lymph nodes Blood



Germinal centers

Primary response

2

Ag

Ag

Tfh

FDC

IgG

BM

Ag

B

1

B

BM

Th

BM

3

4

5

6

BM

Secondary response

IgG

Ag

B

B

B

7

8

**2**

**Figure 2.5.** Generation of B-cell memory responses. Memory B cells are generated in response to T-dependent antigens *(1),* during the germinal center (GC) reaction *(2),* in parallel to plasma cells. At their exit of GCs, these B cells do not differentiate into antibody-secreting plasma cells but into memory B cells *(3)* that transiently migrate through the blood *(4)* toward the extrafollicular areas of spleen and nodes *(5).* They persist there as resting cells until reexposed to their specific antigens *(6).* On secondary antigen exposure, memory B cells readily proliferate and differentiate into plasma cells *(7)* secreting large amounts of high-affinity antibodies that may be detected in the serum *(8)* within a few days after boosting. Ag, antigen; BM, bone marrow; FDC, follicular dendritic cell; IgG, immunoglobulin G; Th, T-helper.

to generate significantly higher antibody levels than primary immunization. Should this not be the case, the effective generation or persistence of memory B cells should be questioned.

The reactivation, proliferation, and differentiation of memory B cells occur without requiring the induction and development of GC responses. This process is, thus, much more rapidly completed than that of primary responses. A window of 4 to 7 days after *H. influenzae b* (Hib) PS immuni- zation was reported as sufficient for high levels of PS-specific vaccine antibodies to appear in the blood of previously primed infants.122 The rapidity with which antigen-specific antibodies appear in the serum is, thus, another hallmark of secondary responses (see [Table 2.6](#_bookmark10)). Slower antibody kinetics suggests that memory B-cell induction, persistence, and/or reactivation may have been suboptimal.

Another hallmark of memory B cells is that they display and secrete antibodies with a markedly higher affinity than those produced by primary plasma cells, as a result of somatic hypermutation and selection. The affinity maturation process that is initiated within the GCs extends for several months after the end of the GC reaction. Consequently, vaccine anti- bodies with higher than baseline avidity (defined as the sum of epitope-specific affinities) for antigen are induced only when sufficient time has elapsed after priming.123–125 A “clas- sical” prime-boost immunization schedule is, thus, to allow 4 to 6 months to elapse between priming and booster doses, hence the generic “0-1-6 month” (prime-prime-boost) sched- ule. Secondary antigen exposure (see [Table 2.6](#_bookmark10)) thus results in the production of higher-affinity antibodies than primary responses.126 Notably, this may not be the case when “natural” priming, for example, through cross-reactive bacteria, has occurred prior to immunization.

**What Are the Determinants of B-Cell Memory Responses?** The factors that drive the differentiation of antigen-specific GC B cells toward plasma cells or memory B cells are poorly understood.50 In response to protein antigens, both cell popu- lations are generated in the same GCs, and their differentia- tion pathway differs only late in the GC reaction. As a rule,

factors enhancing plasma cell differentiation and primary antibody responses (such as increasing the antigen dose or using adjuvants) also support the induction of memory B cells ([Table 2.7](#_bookmark12)). Postbooster antibody titers are, therefore, higher in people with stronger primary responses. For example, higher postbooster anti-HBsAg responses are observed in people with high (e.g., ≥100 IU/L) rather than intermediate (10–99 IU/L) anti-HBsAg after their primary vaccination.127,128 This is likely to reflect the induction of a larger pool of memory B cells.

The dose of antigen is also an important determinant of memory B-cell responses (see [Table 2.7](#_bookmark12)). At priming, higher antigen doses generally favor the induction of plasma cells, whereas lower doses may preferentially drive the induction of immune memory.129 Closely spaced primary vaccine doses may be beneficial for early postprimary antibody responses but not for postbooster antibody responses, as illustrated with meningococcal group C glycoconjugates.130 As a rule, acceler- ated schedules in which a 4- to 6-month window is not included between priming and boosting result in significantly lower booster responses125 (see [Table 2.7](#_bookmark12)). At the time of boosting, a higher antigen content raises stronger booster responses, presumably by recruiting more memory B cells into the response. This is illustrated by higher antibody responses of children immunized with a higher-antigen-dose pertussis vaccine131 or primed with a glycoconjugate vaccine and boosted with a higher concentration PS (20–50 µg of PS) when com- pared with the glycoconjugate (1–3 µg of PS) vaccines.132,133

Residual titers of vaccine antibodies present at time of

boosting directly influence vaccine antibody responses. As a rule, secondary responses to live attenuated viral vaccines are minimal, since preexisting antibodies neutralize the vaccine virus before in vivo replication. Consequently, even multiple doses of live attenuated vaccines do not have undesirable effects. Responses to nonlive vaccines are also negatively influenced by residual vaccine antibody titers. This may reflect the formation of antigen–antibody complexes that reduce the load of antigen available for B-cell binding and/or antibody-mediated negative feedback mechanisms acting directly on B cells through, for example, fragment c (Fc)

|  |  |
| --- | --- |
| **TABLE 2.7** Determinants of Secondary B-Cell Responses | |
| **Determinants** | **Mechanisms (Presumed)** |
| Postprimary antibody titers | As plasma cells and memory responses are generated in parallel in GCs, higher postprimary Ab titers reflect stronger GC reactions and generally predict higher secondary responses. |
| Residual antibodies at boosting | Neutralization of live viral vaccines; negative feedback mechanisms on nonlive vaccines. |
| Lower antigen dose at priming | A limited quantity of antigen may induce B-cell differentiation away from PCs and toward memory B cells (?). |
| Longer intervals before boosting | A minimal interval of 4–6 months is required for optimal affinity maturation of memory B cells. |
| Higher antigen dose at boosting | A higher availability of antigen may drive higher numbers of memory B cells into differentiation. |
| **Antigen Availability** |  |
| Exogenous exposure | Exposure to exogenous antigens may reactivate or favor the persistence of memory B cells. |
| Localization | Memory B cells reactivation requires antigens to reach the draining lymph nodes and not be restricted on mucosal surfaces (HPV, pertussis [?]). |
| In vivo persistence | Antigen persistence may reactivate or favor the persistence of memory B cells. |
| Ab, antibody; GC, germinal center; HPV, human papillomavirus; PC, plasma cell. | |

receptors. Consequently, people with residual antibodies to a given antigen may show only a limited increase of their anti- body responses.

The persistence of memory B cells is of utmost importance for long-term vaccine efficacy. Antigen persistence may extend for prolonged periods on the surface of FDCs (see [Table 2.7](#_bookmark12)) and contribute to the duration of immune memory.134 This is likely to contribute to the extended (indefinite?) memory to live attenuated vaccines, recently exemplified by repeated administration of smallpox vaccines decades after priming.135 Fortunately, memory B cells survive for prolonged periods (e.g., several decades), even in the absence of reexposure to antigen.136 It has been suggested that memory B cells undergo a certain degree of homeostatic polyclonal activation.137 Although this does not seem sufficient to maintain antibody responses,138 it likely contributes to their persistence and the replenishment of BM plasma cells.

The demonstration of the persistence of memory B cells long after vaccine antibodies have eventually disappeared, and of their brisk reactivation on antigen exposure, has direct con- sequences for immunization programs. First, it implies that an immunization schedule should never be started all over again—but continued where interrupted, regardless of the duration of the interruption. Second, it implies that certain immunization schedules may not need to include booster doses, if the individual is exposed to regular natural boosters. It is intriguing to note, that in the absence of childhood boost- ers, up to 50% of adolescents or young adults primed against tetanus or hepatitis B in infancy might not raise anamnestic responses, suggesting that infant-induced vaccine memory may not last forever.139,140

**Immune Memory and Vaccine-Induced Protection: A Race Between Reactivation and Microbial Invasion?** All existing vaccines, except T-independent PS, induce immune memory. Nevertheless, vaccine efficacy may be short-term, as illustrated following infant immunization against group C meningo- coccus.141 Demonstration of priming—or “boostability”—is therefore not a surrogate marker for long-term vaccine efficacy. This requires identifying the determinants that contribute to— or limit—the persistence of vaccine efficacy. One hypothesis is that this essentially results from the race between the reac- tivation of immune memory and disease pathogenesis.142

It is generally considered that protection by toxoid-based vaccines requires the presence of antitoxin antibodies at time of toxin exposure/production. Persisting immune memory

is also not sufficient to protect against *acute* hepatitis B after the waning of vaccine-induced antibodies.143–145 However, pro- gression to chronic liver disease has not been reported in fully immunized vaccine responders. That immune memory is suf- ficient to protect against chronic hepatitis B suggests that viral replication and reexposure to HBsAg efficiently drive vaccine- induced memory cells into effector cells before the end of the viral incubation period (4–12 weeks). This process requires enough HBsAg-specific memory B cells to be stimulated, to persist, and to be capable of reactivation even several decades after infant priming. It remains to be defined whether T-cell memory responses contribute to the maintenance of vaccine- induced protection after waning of anti-HBsAg antibodies.

Glycoconjugate vaccines against encapsulated bacteria illustrate the importance of immune memory for vaccine effi- cacy and some of its limitations. Glycoconjugate priming elicits a bona fide GC reaction, with the induction of high- affinity memory B cells that can be rapidly (4–7 days) recalled on PS immunization.122 Efficient priming (i.e., induction of immune memory) is readily demonstrated in children primed in infancy.146,147 However, immune memory can be seen in children with Hib vaccine failure,148 indicating that their res- ervoir of memory B cells did not protect them against invasive disease, perhaps through a failure of avidity maturation.149 The discrepancy between the existence of memory B cells and the lack of protection may again reflect the race against microbial invasion: the time required for production of sufficient levels of circulating antibodies could be too long to interrupt bacte- rial invasion. Notably, secondary vaccine failures have been relatively rare and primarily observed in countries using an early accelerated infant schedule without a booster dose,150 the use of diphtheria, tetanus, and acellular pertussis (DTaP)/Hib vaccines with lower Hib immunogenicity is also associated with vaccine failure.151 Similarly, glycoconjugate vaccines against group C meningococcal disease proved much more efficacious during the first year after infant priming than during the following 3 years.141 Thus, infant immunization fails to induce sustained protection against group C meningococcus, despite the induction and persistence of immune memory.152 The requirement for boosters to confer long-term vaccine pro- tection is also well illustrated for pertussis, for which boosters are required to extend protection beyond childhood.153 An interesting observation is that vaccine-induced memory per- sists following pertussis immunization—as illustrated by anamnestic responses to a booster dose—but is not sufficient for protection. Yet the incubation period of pertussis exceeds

4 to 7 days. An interesting hypothesis is that as *Bordetella per- tussis* bacteria essentially remain on the mucosal surfaces, anti- gens may fail to efficiently reach the vaccine-induced B and T cells residing in the lymph nodes. For example, the prompt reactivation of immune memory is not sufficient to control polio viral replication in the digestive tract.154

Live attenuated viral vaccines (measles, rubella) are consid- ered the prototype inducers of lifelong immunity, although prolonged immunity is also induced by certain nonlive vac- cines (hepatitis A, HPV, inactivated poliovirus vaccine, rabies). This derives in part from the induction of sustained antibody responses, which, however, tend to slowly decline in the absence of recurrent exposure,155 and might eventually result in a growing proportion of seronegative vaccinated young adults, including women of childbearing age. Whether the reactivation of immune memory will be sufficient to curtail the replication process and confer protection against measles, rubella, or varicella, and whether adult booster doses may become needed after microbial control, are essential ques- tions. The resurgence of mumps outbreaks in fully vaccinated young adults may reflect the induction of low numbers of memory B cells156 and demonstrates that secondary vaccine failure may occur even with live attenuated vaccines.157 The questions, which are central to sustained vaccine efficacy, are usually unresolved at the time of registration of a new vaccine. For example, to vaccinate young girls against HPV requires reassurance that vaccine protection will extend during several decades. HPV infection of the basal epithelial cells can occur within minutes and is not followed by any antigen exposure to the immune system. Thus, antibody persistence will be required for sustained protection. Remarkably, however, the concentration of vaccine antibodies required to neutralize HPV at the site of entry is so minute158 and vaccine-induced community-protection so efficient that boosters may indeed not be needed.



Thus, one may expect questions related to the nature (size, type, responsiveness) of the pool of memory cells elicited by various immunization schedules and the relative contribution of long-term antibodies and immune memory to protection to be at the core of many vaccine studies in the next decades.

## T-Cell Vaccine Responses

**2**

**How Do Vaccines Induce CD4+ and CD8+ T-Cell Responses?** The generation of CD4+ Th-cell response begins when DCs capture antigen in peripheral tissue and migrate to draining lymph nodes, where T-cell vaccine responses are elicited in parallel to B-cell responses (see [Table 2.1](#_bookmark1)). Thus, DCs fulfill a pivotal role in initiating and shaping the immune response to vaccine antigens.

Protein vaccine antigens are taken up by immature DCs activated by local inflammation, which provide the signals required for their migration to draining lymph nodes (see [Fig.](#_bookmark3) [2.1](#_bookmark3)). During this migration, DCs mature and their surface expression of molecules changes.159 Simultaneously, antigens are processed into small fragments and displayed at the cell surface in the grooves of MHC (human leukocyte antigen [HLA] in humans) molecules. As a rule, MHC class I molecules present peptides from antigens that are produced in the cytosol of infected cells, whereas phagocytosed antigens are essentially displayed on MHC class II molecules.160–163 Thus, mature DCs reaching the T-cell zone of lymph nodes display MHC–peptide complexes and high levels of costimulation molecules at their surface.164 CD4+ T cells recognize antigenic peptides displayed by class II MHC molecules, whereas CD8+ T cells bind to class I MHC-peptide complexes ([Fig. 2.6](#_bookmark13)).165 Their recognition is restricted to short peptides (8–11 [CD8+] or 10–18 [CD4+] amino acids) displayed on specific MHC class I or II molecules, respectively. Antigen-specific T-cell receptors may bind only to specific MHC molecules



CD8+

Ag

7

6 –

Cytotoxic T cells

1

DC

8

MHC I

+

2

TNF- IFN-

MHC II

+

5

MHC II

3

4

9

CD4+

Th1

Th2

**Figure 2.6.** Generation of T-cell effector responses. Antigens are phagocytosed by dendritic cells (DCs) *(1),* processed into small peptides, and displayed at the cell surface in the groove of major histocompatibility complex (MHC) class I and/or class II molecules *(2).* CD4+ T cells with the appropriate MHC-peptide specificity are activated, provide activation signals to DCs *(3)*, and differentiate in effector cells *(4)* that produce preferentially T helper (Th)1 or Th2 cytokines. Th1 CD4+ T cells support *(5)* CD8+ T-cell differentiation, which is in contrast inhibited *(6)* by Th2-like cytokines. CD8+ T cells recognize MHC class I-peptide complexes *(7)* and differentiate into cytotoxic effector cells *(8)* capable of killing infected cells *(9)* or pathogens. Ag, antigen; IFN, interferon; TNF, tumor necrosis factor.

(e.g., HLA-A2), which differ among individual people and populations. Consequently, T-cell responses are highly vari- able within a population. These T-cell epitopes may be gener- ated from any region of the vaccine antigens, whether the peptide sequence is located within or at the surface of the protein. This is in contrast with B-cell recognition, which is essentially limited to conformational determinants consti- tuted by amino acids at the antigen surface. This MHC-peptide signal (signal 1) is not sufficient for activation of T cells, which remain anergic or become tolerized in absence of costimula- tion (signal 2). This ensures that only naïve T cells binding to the surface of activated DCs (i.e., DCs that have sensed danger signals through their Toll-like receptors and responded by a modulation of their surface or secreted molecules) receive the costimulation signals required for their activation.164

Activated CD4+ T cells essentially exert supportive functions

for DCs, to which they provide signals (CD40L, etc.) resulting in further activation, for B cells (see [Fig. 2.2](#_bookmark5)) and for CD8+ cytotoxic T cells (see [Fig. 2.6](#_bookmark13) and [Table 2.8](#_bookmark14)). They are elicited by each vaccine type, except plain PS, which are not properly displayed by MHC molecules. Thus, the demonstration of postimmunization CD4+ T-cell responses does not imply a direct role in vaccine efficacy. CD4+ T-cell activation by DCs triggers their differentiation along distinct differentiation pathways.164,166 By default, DCs essentially trigger the induc- tion of Th2-type CD4+ T cells producing IL-4, IL-5, and IL-13, which are implicated in the defense against extracellular pathogens such as helminths.167 More potently activated DCs release IL-12p70, which induces the differentiation into Th1 cells that essentially produce IFN-γ and tumor necrosis factor (TNF)-α and, thus, contribute to the elimination of intracel- lular pathogens directly (cytokine responses) and indirectly through macrophage activation and support to CD8+ T-cell differentiation (see [Fig. 2.6](#_bookmark13)).168 Th1 and Th2 cells support B-cell activation and differentiation during extrafollicular responses, whereas Tfh CD4+ cells provide critical help to GC B cells (see [Fig. 2.3](#_bookmark7)).169 Under certain conditions, activated

DCs may also release IL-23, supporting the induction of inflammatory Th17 cells by TGF-β and IL-6.

Numerous factors influence the preferential differentiation of CD4+ T cells toward the Th1, Th2, Tfh, or Th17 pathway.170 The main determinant of CD4+ T-cell differentiation is the extent and type of DC activation by the innate system,164 although a recent observation suggests that polarized CD4+ T-cell responses may result from preferential expansion rather than priming.171 Consequently, DCs are the primary target for specific adjuvants, which may preferentially skew CD4+ responses toward Th1, Th2, or Th17 responses and impact the differentiation of Tfh cells, requiring their careful design and selection.34–37,39,172

CD8+ T-cell responses are essentially induced as a result of cross-presentation elicited by infectious, live attenuated vac- cines that introduce antigens within the cell cytosol, ensuring their access to MHC class I molecules.163,173 However, novel delivery systems such as live-vectored vaccines or DNA vac- cines delivering antigens directly into the cytosol are now in human trials.174

The activation of naïve T cells by vaccine-bearing DCs may also induce their differentiation into Tregs (see [Table 2.8](#_bookmark14)), a heterogeneous population with many levels of complexity.10,175 Vaccine-induced Tregs may use multiple mechanisms to sup- press T-cell induction or proliferation: in draining lymph nodes, they may prevent DC maturation, block the priming of effector T cells, or destroy antigen-bearing DCs. These Tregs may be elicited as feedback mechanisms to avoid excessive and, thus, potentially harmful inflammatory responses. By suppressing immune responses, Tregs may limit the efficacy of vaccines, for example, when danger signals are insufficient to elicit immunity, as in chronic infections and cancer.176–178 Defining the determinants of Treg differentiation may be needed for novel immunization strategies such as therapeutic vaccines. Preclinical studies indicate that adjuvants improving the ratio of antigen-specific effector to Tregs enhance vaccine immunity,179 opening interesting possibilities.

|  |  |  |
| --- | --- | --- |
| **TABLE 2.8** T-Cell Responses to Vaccines | | |
| **Type** | **Mechanisms (Presumed)** | **Function** |
| **CD4+ T-helper cells** | | |
| Th1 | IFN-γ production | Extrafollicular B-cell help |
| Th1 | Cell contact, IFN-γ | Activation of CD8+ T cells |
| Th1/Th2 | Cell contact, CD40L | Dendritic cell activation |
| Th2 | IL-4, IL-5, IL-13 | Extrafollicular B-cell help |
| Th2 | Cell contact, IL-4 | Suppression of CD8+ T cells |
| Th17 | IL-17, IL-21, IL-22 | Mucosal inflammation |
| **CD4+ follicular T-helper cells** | | |
| Tfh1 | IFN-γ | Germinal center B-cell help |
| Tfh2 | IL-4, IL-5, IL-13 | Germinal center B-cell help |
| **CD4+ regulatory T cells** | Multiple mechanisms | Suppression of CD4+/CD8+ responses |
| **CD8+ T cells** | IFN-γ, TNF-α | Killing of infected cells |
| **Memory T cells** | | |
| Effector memory T cells | Th1/Th2 cytokines, perforin, granzyme | Rapid secondary effectors responses in periphery |
| Central memory T cells | IL-2, IL-10, CD40L | Delayed activation/proliferation in lymph nodes |
| Tissue-resident memory T cells | Th1/Th2 cytokines, perforin, granzyme | Tissue localization enabling immediate-early reactivation |
| IFN, interferon; IL, interleukin; Th, T-helper; TNF, tumor necrosis factor. | | |

## What Are the Determinants of Vaccine-Induced T-Cell Memory?

Effector T-cell responses are short-lived, and most (>90%) effector T cells die by apoptosis within a few days. Thus, immune memory is essential to T-cell vaccine efficacy. It is dependent on four main parameters: the frequency of antigen- specific memory T cells, their phenotype, their persistence, and their localization, a recently identified parameter ([Table](#_bookmark15) [2.9](#_bookmark15)).174,180,181 Memory T cells may persist lifelong, even in the absence of antigen exposure and despite their quality and amount being set during the primary immune response.

The frequency of memory T cells directly reflects the mag- nitude of the initial T-cell expansion and that of its subsequent contraction during which few surviving cells differentiate toward memory T cells. The main determinant of the expan- sion phase is the level of or duration of antigen stimulation present during priming.182 This is a major limitation for non- replicating vaccines, which fail to reach sufficient antigen content and typically require the presence of an adjuvant and/ or booster doses. The contraction phase and the transition toward memory cells take place soon after antigen is cleared, which occurs faster for nonreplicating vaccines. Current efforts are, thus, oriented toward the optimization of the primary expansion phase through adjuvants and/or booster adminis- tration. As vaccine-induced immunity limits the subsequent “take” of a live vaccine by inducing its rapid neutralization, one attractive approach is the use of distinct vaccines for priming and boosting, as the adenovirus priming–modified vaccinia virus Ankara (MVA) boosting combination currently considered against Ebola virus.183–186

The phenotype of memory T cells is also important. Two

main types of memory T cells have been identified (see [Table](#_bookmark14) [2.8](#_bookmark14)) based on their phenotype and function, central memory cells and effector memory cells.187 Central memory T cells (Tcm), like naïve T cells, but better equipped, preferentially traffic through lymph nodes and BM and do not exhibit much cytotoxic capacity but have a high proliferative potential. Their role is to recognize antigens transported by activated DCs into lymph nodes and to rapidly undergo massive proliferation and differentiation, generating a delayed but very large wave of effector cells.188 Effector memory T cells (Tem), closer in phe- notype to recently activated T cells, have a high cytotoxic potential that enables them to immediately recognize the pathogen. As they essentially lack lymph nodes homing recep- tors, it was proposed that Tem recirculate from the blood through nonlymphoid organs, monitoring tissues for the pres- ence of specific microbial peptides.188 A third type of memory

|  |  |
| --- | --- |
| **TABLE 2.9** Determinants of Memory T-Cell Responses | |
| **Main Factors** | **Determinants** |
| Frequency of memory T cells | Magnitude of T-cell expansion (initial antigen load, antigen persistence) |
| Phenotype of memory T cells | |
| Effector memory | Induction favored by prolonged antigen persistence |
| Tissue-resident memory | |
| Central memory | Induction favored by rapid antigen clearance |
| Persistence of memory T cells | Supported by interleukin (IL)-15, IL-7 |

T cells (resident memory T cells [Trm]) was recently recognized as populations of memory T cells which remain settled within specific organs such as the intestine, the lungs, the skin.189 How Trm cells are induced and maintained in the specific organs is not yet fully deciphered, but as Trm were demonstrated as central for the protection against mucosal infections, novel vaccine strategies against viral (influenza, respiratory syncytial virus [RSV]) or bacterial (pertussis) mucosal pathogens will attempt their induction/maintenance.190

Antigen persistence essentially controls the proportion of Tcm and Tem memory cells (see [Table 2.9](#_bookmark15)): Tcm cells pre- dominate when antigen is rapidly cleared, whereas Tem/Trm cells become preponderant when antigen persists, such as in chronic infections.174,180,181 This is a challenge for novel non- replicating vaccines that should induce and maintain sufficient Tem/Trm cells for immediate clearance in infected tissues. The long-term persistence of memory T cells is well established. Through homeostatic proliferation, memory T cells may persist lifelong, even without antigen exposure.180,181,191 Studies of the persistence of vaccinia-induced immune memory have confirmed this observation in humans.192–194

**2**

## How Specific Are Vaccine Immune Responses?

The specificity of vaccine responses is at the center of many debates. Ideally, one would want vaccine-induced responses to be sufficiently broad to extend protection to nonvaccine strains (e.g., for influenza, rotavirus, *S. pneumoniae,* or HPV vaccines) and sufficiently restricted to not elicit cross-reactions to allergens or self-antigens or other undesirable nonspecific effects. The specificity of vaccine responses has received added interest as a number of studies have also reported both posi- tive and negative “nonspecific” effects of vaccinations in low income countries.195,196

As B cells recognize conformational epitopes constituted by distant amino acids, they may bind to antigenic peptides with distinct sequences: It has been estimated that roughly 5% of monoclonal antibodies made against 15 viruses cross- reacted with human proteins.197 That any viral infection is not followed by the induction or flare of an autoimmune disease highlights the importance of regulatory mechanisms suppress- ing responses directed against self-antigens. Indeed, the specificity of antibody responses is well controlled. Although polyclonal stimulation has been suggested to activate memory B cells of distinct specificities,137 this response is not associated with antibody responses. Vaccination with tetanus toxoid was found to expand specific and bystander memory T cells but did not modulate antibody responses to unrelated antigens.198 Altogether, this indicates that the induction of cross-reactive antibody responses is extremely limited, which may be impor- tant in preventing undesirable reactions, but which limits the efficacy of vaccine-induced antibody responses to very few cross-reacting nonvaccine serotypes.199

T cells need to recognize only a few amino acids of anti-

genic peptides displayed by MHC molecules, which offers a much greater potential for cross-reactivity. It has been esti- mated that each T lymphocyte could potentially bind to a million different peptides.197 In addition, memory T cells readily respond to homeostatic cytokines, such that bystander memory T cells of distinct antigen specificity may be tran- siently activated and expand during a flu-like illness or an immunization process.198,200 However, vaccine-induced exac- erbations of autoimmune diseases are very uncommon, probably reflecting the efficacy of regulatory mechanisms limiting the intensity, scope, and duration of the immune responses.201,202

The induction of cross-protective T-cell–mediated responses has been repeatedly observed in murine experimental models,

which suggests that cross-reacting viral vaccines could be based on T-cell responses.203 Yet, convincing examples of het- erologous protective immunity in humans are much more limited, including neonatal BCG protects against leprosy,204 and smallpox vaccine protects against monkeypox.205 In con- trast, the sharing of several T-cell determinants is not sufficient for a single oral polio vaccine strain or influenza strain to confer cross-protection. Consequently, it is tempting to con- clude that heterologous protective immunity essentially comes into play for T-cell–mediated rather than for antibody- mediated protective responses. Accordingly, the heterosub- typic immunity conferred by live attenuated influenza vaccines206,207 could be mediated by T cells and/or by mucosal IgA antibodies.

Nonspecific effects of vaccines are occasionally associated with the fear of immune overload and subsequent enhanced vulnerability to infections, a theory not supported by evidence.208,209

In addition to B and T cells, it was recently recognized that innate cells such as natural killer (NK) cells and monocytes acquire a “trained immunity phenotype” upon exposure to certain pathogens and have given support to the idea that vac- cines can have off-target effects. The epidemiological studies on this subject have been done mainly by a group working in Guinea-Bissau and their thesis is that live vaccines (including BCG, measles, and oral polio vaccine [OPV]) can reduce mor- tality caused by respiratory viral infections, whereas killed vaccines, notably diphtheria, tetanus, and pertussis (DTP), can reverse those effects and even increase mortality.210–213 Data from some other regions are supportive of this theory.214,215 As most of the epidemiological studies have been nonrandom- ized studies, this idea has been met with skepticism, particu- larly as the causes of mortality have been ill-defined. Following a systematic review, the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) on immunization concluded that the available data suggest that BCG “has” and measles vaccine “may have” beneficial effects on all-cause mortality, whereas it neither excluded nor confirmed the pos- sibility of beneficial or deleterious nonspecific effects of DTP vaccines on all-cause mortality.216,217

Immunologists have now begun to study this issue more

comprehensively. Evidence has accrued that BCG strongly stimulates cytokine production and enhances responses to other antigens,218,219 and NK cells—which can develop memory220—are stimulated by BCG to respond to antigens other than mycobacterial.221 The Danish strain of BCG used in Guinea-Bissau is particularly strong in this respect.222 Humans given BCG respond with Th1 and Th17 responses and their stimulated monocytes show increased receptor expres- sion.223,224 Wild measles virus infection in monkeys abolishes immune memory to other antigens,225,226 making it possible that measles vaccine in addition prevents abolition by the natural virus of the child’s ability to respond to other infec- tions.227 The proposed negative effects of killed vaccines on mortality remains for the moment based only on observa- tion,228 although nonlive vaccines typically elicit preferential Th2 responses which might hypothetically reduce the Th1 polarization elicited by live vaccines. This subject is one in evolution and a randomized study has begun in Denmark that should shed light on the importance, if any, of nonspecific or off-target effects in a developed country.228

## Vaccine Responses at the Extremes of Age

**The Challenges of Neonatal and Early Life Immunization.** According to UNICEF estimates, 4 million infants younger than 6 months die yearly of acute infections.229 In more devel- oped countries, mortality has been reduced, but infections

represent a significant proportion of infant hospitalizations. This disease burden is caused by a limited number of patho- gens, such that the availability of a few additional vaccines that would be immunogenic soon after birth would make a huge difference. Early life responses markedly differ from those elicited in mature hosts. The blunting of neonatal immune responses has been regarded for many years as result- ing from “neonatal tolerance,” reflecting the antigen naïveté of the immune system and, subsequently, its immaturity. Recent work has prompted a change of perspective, leading to the recognition that the neonatal and early life immune system is, in contrast, specifically adapted to the unique chal- lenges of early postnatal life and develops over time through poorly defined but tightly regulated processes.

These specific neonatal features first affect innate responses as pattern-recognition receptors elicit responses biased against the induction of proinflammatory cytokines, which could cause harmful alloimmune reactions against maternal anti- gens or excess inflammatory reactions.230,231 In addition, many factors determine the quality and quantity of infant antibody responses: this includes the state of prenatal and postnatal development of the immune system, the type of vaccine and its immunogenicity, the number of doses and their spacing, and the influence of maternal antibodies.232–234

Early life immune responses are characterized by age- dependent limitations of the magnitude of responses ([Table](#_bookmark16) [2.10](#_bookmark16)). Antibody responses to most PS antigens are not elicited during the first 2 years of life, which is likely to reflect numer- ous factors, including the slow maturation of the splenic mar- ginal zone,65,235 limited expression of CD21 on B cells, and limited availability of the complement factors.236 Although this may be circumvented in part by the use of glycoconjugate vaccines, even the most potent glycoconjugate vaccines elicit markedly lower primary IgG responses in young infants.237

Early life antibody responses are directly determined by the prenatal (e.g., gestational age238) and the postnatal age at immunization.236 Accelerated infant vaccine schedules in which three vaccine doses are given at 1-month intervals (2, 3, 4 or 3, 4, 5 months) result in lower immune responses than schedules in which more time elapses between doses (2, 4, 6 months) or between the priming and boosting dose (3, 5, 12 months). However, the magnitude of infant antibody responses to multiple dose schedules reflects the interval between doses, with longer intervals eliciting stronger responses, and the age at which the last vaccine dose is admin- istered. That postnatal immune maturation is required for stronger antibody responses is best demonstrated by compar- ing antibody responses to single-dose vaccines given to anti- gen-naïve infants of various ages.239,240 These studies may be confounded by the persistence of maternal antibodies, which negatively influence infant antibody responses in both epitope and titer specific manners.241,242 Thus, multivariate analyses of the data for a large number of infants are required to identify the main determinants of vaccine antibody responses.243

The induction of B-cell responses is critically dependent on

components of the local microenvironment. However, blood is the only accessible compartment in infants and the factors that specifically limit the magnitude of early life antibody responses are difficult to study. Studies in which vaccines rou- tinely administered to human infants were administered at various stages of the postnatal maturation to infant mice indi- cated that the same limitations of antibody responses are seen in both humans and mice, reflecting similar postnatal con- straints.236 These animal models showed that limitations of antibody responses in early life result from the limited and delayed induction of GCs in which antigen-specific B cells proliferate and differentiate. This was first shown to essentially reflect the delayed development of FDCs required to nucleate

|  |  |
| --- | --- |
| **TABLE 2.10** Limitations of Vaccine Responses at the Extremes of Life (Mechanisms Presumed) | |
| **In Early Life** |  |
| Limited magnitude of Ab responses to PS | Immaturity of marginal zone; low CD21 expression on B cells; limited availability of complement |
| Limited magnitude of Ab responses to proteins | Limited GC responses (delayed FDC development?); inhibitory influence of maternal antibodies |
| Short persistence of Ab responses to proteins | Limited establishment of bone marrow plasma cell pool (survival niches?) |
| Shorter duration of immune memory (?) | Limited GC responses (magnitude of initial memory B-cell pool?) |
| Limited IFN-γ responses | Suboptimal antigen-presenting cell/T-cell interaction (IL-12, IFN-α) |
| Limited CD8+ T-cell responses (?) | Insufficient evidence |
| Influence of maternal antibodies | Inhibition of B-cell but not T-cell responses |
| **In Elderly People** |  |
| Limited magnitude of Ab responses to PS | Low reservoir of IgM+ memory B cells; weaker differentiation into plasma cells |
| Limited magnitude of Ab responses to proteins | Limited GC responses: suboptimal CD4+ helper responses, suboptimal B-cell activation, limited FDC network development?; changes in B-/T-cell repertoire |
| Limited quality (affinity, isotype) of antibodies | Limited GC responses; changes in B-/T-cell repertoire |
| Short persistence of Ab responses to proteins | Limited plasma cell survival? |
| Limited induction of CD4+/CD8+ responses | Decline in naïve T-cell reservoir (accumulation of effector memory and CD8+ T cell clones) |
| Limited persistence of CD4+ responses | Limited induction of new effector memory T cells (IL-2, IL-7) |
| Ab, antibody; FDC, follicular dendritic cell; GC, germinal center; IFN, interferon; Ig, immunoglobulin; IL, interleukin; PS, polysaccharide. | |

**2**

and support GC reactions244 and subsequently to result from the limited induction of Tfh cells in the draining lymph nodes.7,245 Direct evidence for a similar mechanism is difficult to obtain235 in human infants. Efforts are ongoing to identify adjuvants for use in early life. The capacity of the MF59 adju- vant to induce strong Tfh/GC responses in infant mice7 could also be relevant to the ability of the adjuvant to improve the efficacy of influenza vaccines in young children.246

In contrast with this blunting of early life antibody responses, the neonatal immune system readily allows the induction of immune memory, thus reflecting preferential dif- ferentiation of early life GC B cells toward memory rather than Ig-producing plasma cells. Neonatal priming may, thus, be used to initiate vaccine responses against hepatitis B or polio- myelitis. Recent work demonstrated that acellular pertussis vaccines may similarly effectively prime neonatal responses, resulting in faster acquisition of infant immunity.247–249 However, neonatal priming with a combined DTaP vaccine blunted rather than primed subsequent infant pertussis responses,250 and somewhat reduced Hib and HBsAg responses were also seen following neonatal acellular pertussis priming.248,251 Thus, vaccine interference issues may be exacer- bated in early postnatal life, requiring further studies.252

The persistence of immune memory has important impli-

cations, especially for infant immunization programs such as for hepatitis B that are intended to protect throughout adult life. The duration of such responses (e.g., the boostability of hepatitis B vaccine antibody responses primed in infancy) extends for at least one decade. However, in the absence of childhood boosters, the boostability of infant-induced immu- nity may not persist lifelong.139,140

Antibody responses elicited before 12 months of age rapidly wane, and antibody titers soon return to near baseline levels,152,253 which may be associated with a resurgence of vulnerability to infection.141 This likely reflects the limited survival of antigen-specific plasma cells, as confirmed in infant mice244 in which early life BM stromal cells provided insuffi- cient survival signals to plasma cells reaching BM niches.254

Isotype switching and somatic hypermutation (i.e., the affinity maturation of vaccine induced B cells) are already functional in the first year of life,124,255–257 including in preterm infants.238 However, several months are required for affinity maturation even in adults,90 such that high-affinity responses are not observed in very young infants.

Neonatal and infant T-cell responses also differ from those elicited later in life, in particular in the induction of lower IFN-γ236 and higher Th2 and/or Th17 responses.258 As exam- ples, IFN-γ responses to OPV are significantly lower in infants than in adults259; hepatitis B vaccine induces lower primary IFN-γ responses and higher secondary Th2 responses in early life than in adults260; and tetanus-specific IFN-γ CD4+ T-cell responses progressively increase with age.261 Comparing neo- natal and infant priming with acellular pertussis vaccines indi- cated the preferential induction of Th2 responses on neonatal priming.262 Whether this results from the fact that neonatal APC responses to Toll-like and other pathogen-associated molecular pattern receptors produce less IFN-α, IFN-γ, and IL-12p70, and more IL-10 than adult cells,263–265 or result from complex epigenetic controls or the predominance of recent thymic emigrants in neonatal blood,266 is unknown. The con- tribution of other factors, such as the predominance of Tregs that are abundant during fetal life267 and the role of CD71+ immunosuppressive erythroid cells,268 remains to be defined. Remarkably, adult-like Th1 neonatal responses are notoriously elicited by BCG.269 Whether neonatal T cells have higher intrinsic requirements for antigen-specific activation require further investigations.

Importantly, the induction of early life B- and T-cell vaccine

responses takes place in an environment that may be influ- enced by the presence of antibodies of maternal origin. IgG antibodies are actively transferred through the placenta, via the FcRn receptor, from the maternal to the fetal circulation.270 After immunization, maternal antibodies bind to their specific epitopes at the antigen surface, competing with infant B cells and, thus, limiting B-cell activation, proliferation, and differ- entiation. The inhibitory influence of maternal antibodies on

infant B-cell responses affects all vaccine types, although its influence is more marked for live attenuated viral vaccines that may be neutralized by even minute amounts of passive antibodies.271 This inhibition is epitope-specific.272 As a rule, maternal antibodies to carrier proteins (e.g., to tetanus toxoid) blunt infant responses to tetanus toxoid, but not to the PS moiety.273,274 However, responses to conjugate vaccines may be blunted if anticarrier immunity is required for immunogenic- ity (e.g., for CRM197 conjugates) and maternal antibodies inter- fere with its induction.275 Maternal antibodies were reported as inhibiting cotton-rat B-cell responses by interaction with the inhibitory/regulatory FcγRIIB receptor on antigen-specific B cells.276,277 The extent to which this mechanism accounts for the inhibition of human infant responses remains undefined.

The inhibitory influence of maternal antibodies is depen-

dent on the antibody titer and reflects the ratio of maternal antibodies to vaccine antigen.90 This was elegantly demon- strated in a study in which Israeli infants were immunized with hepatitis A vaccine at 2, 4, and 6 months.278 Overall, infant responses were elicited only when maternal antibodies declined to a threshold of 300 to 400 mIU/mL.278 The mater- nal antibody titer at which infant responses may be elicited can be defined only experimentally, by comparing antibody responses in infants stratified according to maternal antibody titers at the time of priming. Few vaccines have these precise antibody levels determined by such experimental studies.

The extent and duration of the inhibitory influence of maternal antibodies, therefore, increase with gestational age,238 for example, with the amount of transferred immuno- globulins, and decline with postnatal age, as maternal anti- bodies wane.90 Increasing the dose of vaccine antigen may be sufficient to circumvent the inhibitory influence of maternal antibodies, as illustrated for hepatitis A,279 measles,280 and the higher content of pertussis toxin in acellular versus whole-cell pertussis281 vaccines. However, the higher titers of maternal antibodies elicited by maternal immunization eventually interfere, even with responses to acellular pertussis vaccines.275,282

Maternal antibodies usually allow a certain degree of priming (i.e., of induction of memory B cells) through yet undefined mechanisms. As a rule, the blunting of infant antibody responses by maternal antibodies disappears after boosting. Importantly, maternal antibodies do not exert their inhibitory influence on infant T-cell responses, which remain largely unaffected or even enhanced.283–285 This is best explained by the fate of maternal antibody–vaccine antigen complexes: immune complexes are taken up by macrophages and DCs, dissociate into their acidic phagolysosome compart- ment, and are processed into small peptides. These peptides are displayed at the surface of APCs and are available for binding by CD4+ and CD8+ T cells.

Thus, the main challenge for further improvement of early life immunization strategies are to identify vaccine formula- tions and strategies capable of inducing, after one or two early doses, the strong primary antibody responses required against certain early life pathogens—despite the presence of maternal antibodies. Importantly, these formulations/strategies will have to be demonstrated as safe in immunologically immature hosts, adding to the challenges.286

**Age-Associated Changes in Vaccine Responses.** Innate and adaptive antibody and T-cell–mediated cellular immune

responses decline with age, which increases the frequency and severity of infections and reduces the protective effects of vaccinations.287 Aging affects the magnitude and the persistence of antibody responses to protein vaccines,288,289 as reflected by lower serum antibodies to influenza,290,291 tetanus, and tick- borne encephalitis (TBE) vaccines.292 It also affects responses to pneumococcal PS vaccines, although differences in method- ological issues have yielded contradictory results.293 Remark- ably, the limitation of antibody responses by aging occurs early: After the age of 20 years, each 10-year period reduced antibody titers elicited by a potent adjuvanted pandemic influenza vaccine in healthy control subjects and immunosuppressed patients by 31%.294 Limitations of antibody responses in elderly people are also associated with qualitative changes that affect antibody specificity, isotype, and affinity, that is, functional efficacy (see [Table 2.10](#_bookmark16)).295,296

They result from the influence of a large number of under-

lying events.232,297 Responses to PS vaccines are conditioned by a decline in the reservoir of IgM+ memory B cells that differ- entiate less efficiently into antibody producing cells, and, thus, limit the IgM responses of aged people.298 Antibody responses relying on the induction of GCs are also limited,299 affecting the magnitude of antibody responses and resulting into anti- bodies of weaker affinities/functional capacities296 and distri- bution of subclass antibodies.300 Numerous factors contribute to limiting the induction of GCs in elderly persons, including factors that are intrinsic to B cells301 and that affect other cell types, including Tfh cells.302 For example, studies in aged mice have convincingly demonstrated the existence of age-related changes in FDCs.303,304 The limited ability of aged subjects to generate high-affinity antibody responses also reflects changes in their antibody repertoire.304,305

Age-associated changes in T-cell responses are reflected by

a progressive decline in naïve T cells, reflecting declining thymic output. This is associated with a marked accumulation of large CD8+ clones presumably resulting from prior infec- tions. These large T-cell clones (e.g., elicited in response to cytomegalovirus) have reached a state of replicative senes- cence, and homeostatic mechanisms negatively influence the size of the naïve and effector memory T-cell subsets.289 In response to influenza immunization, healthy elderly people mount CD4+ responses initially similar to those of young adults but that fail to maintain or expand.306 This does not reflect a functional impairment of CD4+ T memory cells,307 but a shift of the T-cell pool from naïve to memory effector CD4+ T cells. The failure to maintain CD4+ responses reflects a lower induction of new Tem cells in relation to lower IL-7 levels.306,307 Other studies indicated that frail elderly subjects mount blunted and delayed Th1 responses to influenza vaccination, which correlated positively with their reduced total and IgG1 antibody response.308 Limitations also affect the expansion of infection-driven influenza-specific CD8+ T cells.308 Strategies to enhance vaccine-induced protection in aging people include the use of higher vaccine doses309 and/or specific adjuvants. This was recently demonstrated by formulating the IgE glyco- protein of varicella-zoster in the novel AS01E adjuvant.24 Nev- ertheless, limitations of effector memory and of GC responses may continue to require the more frequent administration of certain vaccine boosters (e.g., against tetanus or TBE308) to compensate for the brevity of B- and T-cell vaccine-induced responses in elderly people.

References for this chapter are available at [ExpertConsult.com](http://www.ExpertConsult.com/).

REFERENCES

1. Pulendran B. Systems vaccinology: probing humanity’s diverse immune systems with vaccines. *Proc Natl Acad Sci USA*. 2014;111(34):12300-12306.
2. Cooper NR, Nemerow GR. The role of antibody and comple- ment in the control of viral infections. *J Invest Dermatol*. 1984;83(1 suppl):121s-127s.
3. Geginat J, Paroni M, Maglie S, et al. Plasticity of human CD4 T cell subsets. *Front Immunol*. 2014;5:630.
4. Crotty S. A brief history of T cell help to B cells. *Nat Rev Immunol*. 2015;15(3):185-189.
5. Bentebibel S, Lopez S, Obermoser G, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses toinfluenzavaccination. *Sci Transl Med*. 2013;5:176ra32.
6. Spensieri F, Borgogni E, Zedda L, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. *Proc Natl Acad Sci USA*. 2013;110:14330-14335.
7. Mastelic Gavillet B, Eberhardt CS, Auderset F, et al. MF59 medi- ates its B cell adjuvanticity by promoting T follicular helper cells and thus germinal center responses in adult and early life. *J Immunol*. 2015;194(10):4836-4845.
8. Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. *Semin Immunopathol*. 2010;32:79-90.
9. Kumar P1, Chen K, Kolls JK. Th17 cell based vaccines in mucosal immunity. *Curr Opin Immunol*. 2013;25(3):373-380.
10. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol*. 2010;10:490-500.
11. Igietseme JU, Eko FO, He Q, et al. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracel- lular pathogens. *Expert Rev Vaccines*. 2004;3:23-34.
12. Weintraub A. Immunology of bacterial polysaccharide antigens.

*Carbohydr Res*. 2003;338:2539-2547.

1. Lindberg AA. Polyosides (encapsulated bacteria). *C R Acad Sci*

*III*. 1999;322:925-932.

1. Lockhart S. Conjugate vaccines. *Expert Rev Vaccines*. 2003;2:633-648.
2. Nunes-Alves C, Booty MG, Carpenter SM, et al. *Nat Rev Micro- biol*. 2014;12:289-299.
3. Gnann JW Jr, Whitley RJ. Herpes zoster. *N Engl J Med*. 2002;347:340-346.
4. Plotkin SA. Vaccines: correlates of vaccine-induced immunity.

*Clin Infect Dis*. 2008;47(3):401-409.

1. Plotkin SA. Complex correlates of protection after vaccination.

*Clin Infect Dis*. 2013;56(10):1458-1465.

1. Casadevall A. The methodology for determining the efficacy of antibody-mediated immunity. *J Immunol Methods*. 2004;291: 1-10.
2. Trotter CL, McVernon J, Ramsay ME, et al. Optimising the use of conjugate vaccines to prevent disease caused by *Haemophilus influenzae* type b, *Neisseria meningitidis* and *Streptococcus pneu- moniae*. *Vaccine*. 2008;26:4434-4445.
3. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide con- jugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med*. 2015;372(12):1114-1125.
4. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. *Am J Respir Crit Care Med*. 2010;182:1073- 1079.
5. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med*. 2005;352:2271-2284.
6. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adju- vanted herpes zoster subunit vaccine in older adults. *N Engl J Med*. 2015;372(22):2087-2096.
7. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. *J Pediatr*. 1998;132:983-988.
8. Salmaso S, Mastrantonio P, Tozzi AE, et al.; the Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. *Pediatrics*. 2001;108:E81.
9. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immunity and antibody responses to *Bordetella pertussis* antigens in chil- dren with a history of pertussis infection and in recipients of an acellular pertussis vaccine. *J Infect Dis*. 2000;181:1989-1995.
10. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. *Infect Immun*. 1999;67:4064- 4071.

**2**

1. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmis- sion in a nonhuman primate model. *Proc Natl Acad Sci USA*. 2014;111(2):787-792.
2. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. *Mucosal Immunol*. 2013;6(4):787-796.
3. Smits K, Pottier G, Smet J, et al. Different T-cell memory in preadolescents after whole-cell or acellular pertussis vaccination. *Vaccine*. 2013;32(1):111-118.
4. Kurubi J, Vince J, Ripa P, et al. Immune response to measles vaccine in 6 month old infants in Papua New Guinea. *Trop Med Int Health*. 2009;14:167-173.
5. Gans HA, Yasukawa LL, Zhang CZ, et al. Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vac- cinated infants. *Viral Immunol*. 2008;21:163-172.
6. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. *Immunity*. 2010;33:492-503.
7. Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. *Immune Netw*. 2015;15(2):51-57.
8. O’Hagan DT, Fox CB. New generation adjuvants—from empiri- cism to rational design. *Vaccine*. 2015;33(suppl 2):B14-B20.
9. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. *Proc Natl Acad Sci USA*. 2014;111(34): 12294-12299.
10. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. *Science*. 2010;327:291-295.
11. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. *Immunity*. 2010;33:464-478.
12. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. *Immunol Rev*. 2009;227:221-233.
13. Querec T, Bennouna S, Alkan S, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. *J Exp Med*. 2006;203: 413-424.
14. Zabel F1, Kündig TM, Bachmann MF. Virus-induced humoral immunity: on how B cell responses are initiated. *Curr Opin Virol*. 2013;3(3):357-362.
15. Hong Kong Measles Vaccine Committee. Comparative trial of live attenuated measles vaccine in Hong Kong by intramuscular and intradermal injection. *Bull World Health Organ*. 1967;36:375- 384.
16. Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. *Curr Top Microbiol Immunol*. 2009;333:369-393.
17. de Lalla F, Rinaldi E, Santoro D, et al. Immune response to hepatitis B vaccine given at different injection sites and by dif- ferent routes: a controlled randomized study. *Eur J Epidemiol*. 1988;4:256-258.
18. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intra- nasal influenza vaccine and the risk of Bell’s palsy in Switzer- land. *N Engl J Med*. 2004;350:896-903.
19. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controver- sial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. *Eur J Immunol*. 2010;40:638-642.
20. Meier S, Bel M, L’Huillier A, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocom- promised children. *Vaccine*. 2011;29:3548-3557.
21. Pierce SK, Liu W. The tipping points in the initiation of B cell signalling: how small changes make big differences. *Nat Rev Immunol*. 2010;10:767-777.
22. Goodnow CC, Vinuesa CG, Randall KL, et al. Control systems and decision making for antibody production. *Nat Immunol*. 2010;11:681-688.
23. Tarlinton D, Good-Jacobson K. Diversity among memory B cells: origin, consequences, and utility. *Science*. 2013;341(6151): 1205-1211.
24. Reif K, Ekland EH, Ohl L, et al. Balanced responsiveness to che- moattractants from adjacent zones determines B-cell position. *Nature*. 2002;416:94-99.
25. MacLennan IC, Toellner KM, Cunningham AF, et al. Extrafollicu- lar antibody responses. *Immunol Rev*. 2003;194:8-18.
26. Deenick EK, Hasbold J, Hodgkin PD. Decision criteria for resolv- ing isotype switching conflicts by B cells. *Eur J Immunol*. 2005;35:2949-2955.
27. De Silva NS, Klein U. Dynamics of B cells in germinal centers.

*Nat Rev Immunol*. 2015;15(3):137-148.

1. Linterman MA, Vinuesa CG. T follicular helper cells during immunity and tolerance. *Prog Mol Biol Transl Sci*. 2010;92: 207-248.
2. Crotty S. Follicular helper CD4 T cells (T(FH)). *Annu Rev Immunol*. 2011;29:621-663.
3. Rasheed MA1, Latner DR, Aubert RD, et al. Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. *J Virol*. 2013;87(13):7737-7746.
4. Flehmig B, Staedele H, Xueref C, et al. Early appearance of neu- tralizing antibodies after vaccination with an inactivated hepa- titis A vaccine. *J Infect*. 1997;35:37-40.
5. Lucas AH, Reason DC. Polysaccharide vaccines as probes of anti- body repertoires in man. *Immunol Rev*. 1999;171:89-104.
6. Zhou J, Lottenbach KR, Barenkamp SJ, et al. Somatic hypermuta- tion and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of *Streptococcus pneumoniae* type 6B. *Infect Immun*. 2004;72:3505-3514.
7. Vinuesa CG, Sze DM, Cook MC, et al. Recirculating and germi- nal center B cells differentiate into cells responsive to polysac- charide antigens. *Eur J Immunol*. 2003;33:297-305.
8. Weill JC, Weller S, Reynaud CA. Human marginal zone B cells.

*Annu Rev Immunol*. 2009;27:267-285.

1. Zandvoort A, Timens W. The dual function of the splenic mar- ginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne anti- gens. *Clin Exp Immunol*. 2002;130:4-11.
2. Timens W, Boes A, Rozeboom-Uiterwijk T, et al. Immaturity of the human splenic marginal zone in infancy: possible contribu- tion to the deficient infant immune response. *J Immunol*. 1989;143:3200-3206.
3. Southern J, Deane S, Ashton L, et al. Effects of prior polysac- charide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. *Clin Diagn Lab Immunol*. 2004;11:1100-1104.
4. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. *Nat Rev Immunol*. 2009;9:213-220.
5. O’Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? *Lancet Infect Dis*. 2007;7(9):597- 606.
6. Poolman J, Borrow R. Hyporesponsiveness and its clinical impli- cations after vaccination with polysaccharide or glycoconjugate vaccines. *Expert Rev Vaccines*. 2011;10(3):307-322.
7. Russell FM, Carapetis JR, Balloch A, et al. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age: a randomized controlled trial. *Vaccine*. 2010;28:3341-3349.
8. Torling J, Hedlund J, Konradsen HB, et al. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle- aged and elderly persons previously treated for pneumonia. *Vaccine*. 2003;22:96-103.
9. Sigurdardottir ST, Center KJ, Davidsdottir K. Decreased immune response to pneumococcal conjugate vaccine after 23-valent pneumococcal polysaccharide vaccine in children. *Vaccine*. 2014;32(3):417-424.
10. Papadatou I, Piperi C, Alexandraki K, et al. Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. *Clin Infect Dis*. 2014;59(6):862-865.
11. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conju- gate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. *J Infect Dis*. 2012;205(9):1408-1416.
12. Brynjolfsson SF, Henneken M, Bjarnarson SP, et al. Hyporespon- siveness following booster immunization with bacterial polysac- charides is caused by apoptosis of memory B cells. *J Infect Dis*. 2012;205(3):422-430.
13. Baxter D. Vaccine responsiveness in premature infants. *Hum Vaccin*. 2010;6:506-511.
14. Lindberg AA. Glycoprotein conjugate vaccines. *Vaccine*. 1999;17(suppl 2):S28-S36.
15. Pichichero ME. Protein carriers of conjugate vaccines: character- istics, development, and clinical trials. *Hum Vaccin Immunother*. 2013;9(12):2505-2523.
16. Baraldo K, Mori E, Bartoloni A, et al. Combined conjugate vac- cines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. *Infect Immun*. 2005;73:5835-5841.
17. Rabian C, Tschöpe I, Lesprit P, et al. Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumo- coccal vaccine and antibody response to pneumococcal vaccina- tion in HIV-infected adults. *Clin Infect Dis*. 2010;50(8): 1174-1183.
18. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. *Ann N Y Acad Sci*. 1995;754:35-47.
19. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. *Vaccine*. 2010;28:5513-5523.
20. Bixler GS Jr, Eby R, Dermody KM, et al. Synthetic peptide repre- senting a T-cell epitope of CRM197 substitutes as carrier mole- cule in a *Haemophilus influenzae* type B (Hib) conjugate vaccine. *Adv Exp Med Biol*. 1989;251:175-180.
21. Benhamou E, Courouce AM, Jungers P, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. *Clin Nephrol*. 1984;21:143-147.
22. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemo- dialysis patients. *MMWR Recomm Rep*. 2001;50(RR–5):1-43.
23. Dormitzer PR, Galli G, Castellino F, et al. Influenza vaccine immunology. *Immunol Rev*. 2011;239:167-177.
24. Kracker S, Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination [published online ahead of print February 13, 2011]. *Immunol Lett*. 2011;138:97-103.
25. Doria-Rose NA, Joyce MG. Strategies to guide the antibody affin- ity maturation process. *Curr Opin Virol*. 2015;11:137-147.
26. Anttila M, Eskola J, Ahman H, et al. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. *Vaccine*. 1999;17:1970-1977.
27. Siegrist CA, Pihlgren M, Tougne C, et al. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti–hepatitis B vaccine response. *Vaccine*. 2004;23:615-622.
28. Khurana S, Verma N, Yewdell JW, et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. *Sci Transl Med*. 2011;3(85):85ra48.
29. Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. *Vaccine*. 2015;33(32):3953- 3962.
30. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. *Pharmacogenomics*. 2009;10:837- 852.
31. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. *Immunity*. 2010;33:530-541.
32. Pulendran B, Li S, Nakaya HI. Systems vaccinology. *Immunity*. 2010;33:516-529.
33. Pulendran B. Systems vaccinology: probing humanity’s diverse immune systems with vaccines. *Proc Natl Acad Sci USA*. 2014;111(34):12300-12306.
34. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine adminis- tered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. *Hum Vaccin*. 2011;7(12):1374-1386.
35. Krajden M, Cook D, Yu A, et al. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial. *Clin Vaccine Immunol*. 2011;18:418-423.
36. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. *Lancet Oncol*. 2015;16(7):775-786.
37. Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccina- tion against genital warts: A nationwide study of 550 000 young girls. *Clin Infect Dis*. 2015;61(5):676-682.
38. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. *JAMA*. 2013;309(17):1793-1802.
39. Elgueta R, de Vries VC, Noelle RJ. The immortality of humoral immunity. *Immunol Rev*. 2010;236:139-150.
40. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. *Immunol Rev*. 2010;236:125-138.
41. Kometani K, Kurosaki T. Differentiation and maintenance of long-lived plasma cells. *Curr Opin Immunol*. 2015;33:64-69.
42. Halliley JL, Tipton CM, Liesveld J, et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. *Immunity*. 2015;43(1):132-145.
43. Winter O, Moser K, Mohr E, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. *Blood*. 2010;116:1867-1875.
44. Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. *Nat Immunol*. 2011;12:151-159.
45. Zehentmeier S, Roth K, Cseresnyes Z, et al. Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells. *Eur J Immunol*. 2014;44(8):2306-2317.
46. Belnoue E, Tougne C, Rochat AF, et al. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. *J Immunol*. 2012;188(3):1283-1291.
47. Honorati MC, Palareti A, Dolzani P, et al. A mathematical model predicting anti–hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. *Clin Exp Immunol*. 1999;116:121-126.
48. Van Herck K, Beutels P, Van Damme P, et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. *J Med Virol*. 2000;60:1-7.
49. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. *Gynecol Oncol*. 2009;115(3 suppl):S1-S6.
50. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus– like particle (VLP) type 16 prophylactic vaccine. *Vaccine*. 2007;25:4324-4333.
51. Kasturi SP, Skountzou J, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. *Nature*. 2011;470:543-547.
52. Einstein MH, Takacs P, Chatterjee A, et al. Comparison of long- term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analy- sis of a Phase III randomized trial. *Hum Vaccin Immunother*. 2014;10(12):3435-3445.
53. Bock HL, Loscher T, Scheiermann N, et al. Accelerated schedule for hepatitis B immunization. *J Travel Med*. 1995;2:213-217.
54. Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new acceler- ated vaccination schedule for rapid protection against hepatitis A and B. *Vaccine*. 2002;20:1157-1162.
55. Tejiokem MC, Gouandjika I, Béniguel L, et al. HIV-infected chil- dren living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. *PLoS ONE*. 2007;2(12):e1260.
56. Kurosaki T, Kometani K, Wataru I. Memory B cells. *Nat Rev Immunol*. 2015;15:149-159.
57. Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. *J Immunol*. 2010;185:3117-3125.
58. Suan D, Nguyen A, Moran I, et al. T follicular helper cells have distinct modes of migration and molecular signatures in naive and memory immune responses. *Immunity*. 2015;42(4): 704-718.

**2**

1. Pichichero ME, Voloshen T, Passador S. Kinetics of booster responses to *Haemophilus influenzae* type B conjugate after combined diphtheria–tetanus–acellular pertussis–*Haemophilus influenzae* type b vaccination in infants. *Pediatr Infect Dis J*. 1999;18:1106-1108.
2. Brown SE, Howard CR, Zuckerman AJ, et al. Affinity of antibody responses in man to hepatitis B vaccine determined with syn- thetic peptides. *Lancet*. 1984;2:184-187.
3. Ekstrom N, Ahman H, Verho J, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vac- cines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. *Infect Immun*. 2005;73:369-377.
4. Cassidy WM, Watson B, Ioli VA, et al. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. *Pediatrics*. 2001;107:626-631.
5. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by *Haemophilus influenzae type* b conjugate vaccines following infant immunization. *J Infect Dis*. 1998;177:1112-1115.
6. Zanetti AR, Mariano A, Romano L, et al. Long-term immunoge- nicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. *Lancet*. 2005;366:1379-1384.
7. Duval B, Gilca V, Boulianne N, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low ende- micity country. *Pediatr Infect Dis J*. 2005;24:213-218.
8. Ahman H, Kayhty H, Vuorela A, et al. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. *Vaccine*. 1999;17:2726-2732.
9. Borrow R, Goldblatt D, Finn A, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of menin- gococcal C–tetanus toxoid conjugate vaccine in infants in the United Kingdom. *Infect Immun*. 2003;71:5549-5555.
10. Hendrikx LH, Berbers GA, Veenhoven RH, et al. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. *Vaccine*. 2009;27:6530-6536.
11. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide– meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. *Vaccine*. 2000;18:2359-2367.
12. Huebner RE, Mbelle N, Forrest B, et al. Long-term antibody levels and booster responses in South African children immu- nized with nonavalent pneumococcal conjugate vaccine. *Vaccine*. 2004;22:2696-2700.
13. Gray D, Skarvall H. B-cell memory is short-lived in the absence of antigen. *Nature*. 1988;336:70-73.
14. Crotty S, Felgner P, Davies H, et al. Cutting edge: long-term B cell memory in humans after smallpox vaccination. *J Immunol*. 2003;171:4969-4973.
15. Maruyama M, Lam KP, Rajewsky K. Memory B-cell persistence is independent of persisting immunizing antigen. *Nature*. 2000;407:636-642.
16. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of sero- logical memory by polyclonal activation of human memory B cells. *Science*. 2002;298:2199-2202.
17. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long- lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. *J Immunol*. 2008;180:361-371.
18. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. *Pediatr Infect Dis J*. 2008;27:881-885.
19. Posfay-Barbe KM, Kobela M, Sottas C, et al. Frequent failure of adolescent booster responses to tetanus toxoid despite infant immunization: waning of infancy-induced immune memory? *Vaccine*. 2010;28:4356-4361.
20. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after intro- duction. *Lancet*. 2004;364:365-367.
21. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? *Pediatrics*. 2009;124:1633-1641.
22. Young BW, Lee SS, Lim WL, et al. The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers. *J Viral Hepat*. 2003;10:23-30.
23. Lin YC, Chang MH, Ni YH, et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. *J Infect Dis*. 2003;187:134-138.
24. Whittle HC, Maine N, Pilkington J, et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. *Lancet*. 1995;345:1089-1092.
25. Makela PH, Kayhty H, Leino T, et al. Long-term persistence of immunity after immunisation with *Haemophilus influenzae* type b conjugate vaccine. *Vaccine*. 2003;22:287-292.
26. Weinberg GA, Einhorn MS, Lenoir AA, et al. Immunologic priming to capsular polysaccharide in infants immunized with *Haemophilus influenzae* type b polysaccharide–*Neisseria meningiti- dis* outer membrane protein conjugate vaccine. *J Pediatr*. 1987;111:22-27.
27. McVernon J, Johnson PD, Pollard AJ, et al. Immunologic memory in *Haemophilus influenzae* type b conjugate vaccine failure. *Arch Dis Child*. 2003;88:379-383.
28. Lee YC, Kelly DF, Yu LM, et al. *Haemophilus influenzae* type b vaccine failure in children is associated with inadequate production of high-quality antibody. *Clin Infect Dis*. 2008;46:186-192.
29. Ramsay ME, McVernon J, Andrews NJ, et al. Estimating *Hae- mophilus influenzae* type b vaccine effectiveness in England and Wales by use of the screening method. *J Infect Dis*. 2003;188:481-485.
30. McVernon J, Andrews N, Slack MP, et al. Risk of vaccine failure after *Haemophilus influenzae* type b (Hib) combination vaccines with acellular pertussis. *Lancet*. 2003;361:1521-1523.
31. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. *J Infect Dis*. 1999;179:1569-1572.
32. Lee GM, Lebaron C, Murphy TV, et al. Pertussis in adolescents and adults: should we vaccinate? *Pediatrics*. 2005;115: 1675-1684.
33. Abbink F, Buisman AM, Doornbos G, et al. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. *J Infect Dis*. 2005;191:990-999.
34. Davidkin I, Peltola H, Leinikki P, et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination: a 15-year follow-up in Finland. *Vaccine*. 2000;18:3106-3112.
35. Latner DR, McGrew M, Williams N, et al. Enzyme-linked immu- nospot assay detection of mumps-specific antibody-secreting B cells as an alternative method of laboratory diagnosis. *Clin Vaccine Immunol*. 2011;18(1):35-42.
36. Dayan GH, Quinlisk MP, Parker AA, et al. Recent resurgence of mumps in the United States. *N Engl J Med*. 2008;358: 1580-1589.
37. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. *Cell Host Microbe*. 2010;8:260-270.
38. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. *Nat Rev Immunol*. 2005;5:617-628.
39. Groothuis TA, Griekspoor AC, Neijssen JJ, et al. MHC class I alleles and their exploration of the antigen-processing machin- ery. *Immunol Rev*. 2005;207:60-76.
40. Shastri N, Cardinaud S, Schwab SR, et al. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. *Immunol Rev*. 2005;207:31-41.
41. Jutras I, Desjardins M. Phagocytosis: at the crossroads of innate and adaptive immunity. *Annu Rev Cell Dev Biol*. 2005;21: 511-527.
42. Joffre OP, Segura E, Savina A, et al. Cross-presentation by den- dritic cells. *Nat Rev Immunol*. 2012;12:557-569.
43. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. *Nat Rev Immunol*. 2003;3:984-993.
44. Krogsgaard M, Davis MM. How T cells “see” antigen. *Nat Immunol*. 2005;6:239-245.
45. Ahlers JD, Belyakov IM. Molecular pathways regulating CD4+ T cell differentiation, anergy and memory with implications for vaccines. *Trends Mol Med*. 2010;16:478-491.
46. Stetson DB, Voehringer D, Grogan JL, et al. Th2 cells: orchestrat- ing barrier immunity. *Adv Immunol*. 2004;83:163-189.
47. O’Garra A, Robinson D. Development and function of T helper 1 cells. *Adv Immunol*. 2004;83:133-162.
48. Vinuesa CG, Tangye SG, Moser B, et al. Follicular B helper T cells in antibody responses and autoimmunity. *Nat Rev Immunol*. 2005;5:853-865.
49. Swain SL. CD4 T cell development and cytokine polarization: an overview. *J Leukoc Biol*. 1995;57:795-798.
50. Becattini S, Latorre D, Mele F, et al. T cell immunity. Functional heterogeneity of human memory CD4+ T cell clones primed by pathogens or vaccines. *Science*. 2015;347(6220):400-406.
51. Duthie MS, Windish HP, Fox CB, et al. Use of defined TLR ligands as adjuvants within human vaccines. *Immunol Rev*. 2011;239:178-196.
52. Yewdell JW, Haeryfar SM. Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. *Annu Rev Immunol*. 2005;23:651-682.
53. Robinson HL, Amara RR. T cell vaccines for microbial infections.

*Nat Med*. 2005;11(4 suppl):S25-S32.

1. Campbell DJ, Koch MA. Phenotypical and functional specializa- tion of FOXP3+ regulatory T cells. *Nat Rev Immunol*. 2011;11:119-130.
2. Boer MC, Joosten SA, Ottenhoff TH. Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination. *Front Immunol*. 2015;6:217.
3. Wing JB, Sakaguchi S. Foxp3+ T(reg) cells in humoral immunity.

*Int Immunol*. 2014;26(2):61-69.

1. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. *J Clin Invest*. 2005;115:3623- 3633.
2. Perret R, Sierro SR, Botelho NK, et al. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. *Cancer Res*. 2013;73(22):6597-6608.
3. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. *Nat Rev Immunol*. 2014;14(1):24-35.
4. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. *Annu Rev Immunol*. 2013;31:137-161.
5. Wherry EJ, Puorro KA, Porgador A, et al. The induction of virus- specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. *J Immunol*. 1999;163:3735-3745.
6. Dalmia N, Ramsay AJ. Prime-boost approaches to tuberculosis vaccine development. *Expert Rev Vaccines*. 2012;11(10): 1221-1233.
7. Hill AV, Reyes-Sandoval A, O’Hara G, et al. Prime-boost vectored malaria vaccines: progress and prospects. *Hum Vaccin*. 2010;6(1): 78-83.
8. Goepfert P, Bansal A. Human immunodeficiency virus vaccines.

*Infect Dis Clin North Am*. 2014;28(4):615-631.

1. Zhou Y, Sullivan NJ. Immunology and evolvement of the adeno- virus prime, MVA boost Ebola virus vaccine. *Curr Opin Immunol*. 2015;35:131-136.
2. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. *Curr Opin Immunol*. 2005;17:326-332.
3. Huehn J, Siegmund K, Hamann A. Migration rules: functional properties of naive and effector/memory-like regulatory T cell subsets. *Curr Top Microbiol Immunol*. 2005;293:89-114.
4. Schenkel JM, Masopust D. Tissue-resident memory T cells. *Immu- nity*. 2014;41(6):886-897.
5. Zens KD, Farber DL. Memory CD4 T cells in influenza. *Curr Top Microbiol Immunol*. 2015;386:399-421.
6. Marsden VS, Kappler JW, Marrack PC. Homeostasis of the memory T cell pool. *Int Arch Allergy Immunol*. 2006;139: 63-74.
7. Combadiere B, Boissonnas A, Carcelain G, et al. Distinct time effects of vaccination on long-term proliferative and IFN- gamma-producing T cell memory to smallpox in humans. *J Exp Med*. 2004;199:1585-1593.
8. Kennedy JS, Frey SE, Yan L, et al. Induction of human T cell– mediated immune responses after primary and secondary small- pox vaccination. *J Infect Dis*. 2004;190:1286-1294.
9. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of anti- viral immunity after smallpox vaccination. *Nat Med*. 2003;9:1131-1137.
10. Fine PE. Non-specific “non-effects” of vaccination. *BMJ*. 2004;329:1297-1298.
11. Shann F. Heterologous immunity and the nonspecific effects of vaccines: a major medical advance? *Pediatr Infect Dis J*. 2004;23:555-558.
12. Oldstone MB. Molecular mimicry and immune-mediated dis- eases. *FASEB J*. 1998;12:1255-1265.
13. Di Genova G, Roddick J, McNicholl F, et al. Vaccination of human subjects expands both specific and bystander memory T cells but antibody production remains vaccine-specific. *Blood*. 2006;107:2806-2813.
14. Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts com- munities, 2001 and 2004. [published correction appears in Pedi- atrics 117:593–594, 2006]. *Pediatrics*. 2005;116:e408-e413.
15. Mayer S, Laumer M, Mackensen A, et al. Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. *Immunobiology*. 2002;205:282-289.
16. Wraith DC, Goldman M, Lambert PH. Vaccination and autoim- mune disease: what is the evidence? *Lancet*. 2003;362: 1659-1666.
17. Bacchetta R, Gregori S, Roncarolo MG. CD4+ regulatory T cells: mechanisms of induction and effector function. *Autoimmun Rev*. 2005;4:491-496.
18. Vieira GF, Chies JA. Immunodominant viral peptides as deter- minants of cross-reactivity in the immune system: can we develop wide spectrum viral vaccines? *Med Hypotheses*. 2005;65:873-879.
19. Cunha SS, Rodrigues LC, Pedrosa V, et al. Neonatal BCG protec- tion against leprosy: a study in Manaus, Brazilian Amazon. *Lepr Rev*. 2004;75:357-366.
20. Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. *Nat Med*. 2005;11:1005-1011.
21. Gaglani MJ, Piedra PA, Herschler GB, et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold- adapted influenza virus vaccine against the 2000–2001 influenza A(H1N1) and B epidemic in healthy children. *Arch Pediatr Adolesc Med*. 2004;158:65-73.
22. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. *J Infect Dis*. 2000;181:1133-1137.
23. Offit PA, Quarles J, Gerber MA, et al. Addressing parents’ con- cerns: do multiple vaccines overwhelm or weaken the infant’s immune system? *Pediatrics*. 2002;109:124-129.
24. Stowe J, Andrews N, Taylor B, et al. No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine. *Vaccine*. 2009;27:1422-1425.
25. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. *Lancet*. 2003;361(9376):2183-2188.
26. Aaby P, Martins CL, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on child- hood mortality: randomised controlled trial. *BMJ*. 2010;341: c6495.
27. Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and con- ceptual challenges. *Nat Immunol*. 2014;15(10):895-899.
28. Jensen KJ, Karkov HS, Lund N, et al. The immunological effects of oral polio vaccine provided with BCG vaccine at birth: a randomised trial. *Vaccine*. 2014;32(45):5949-5956.
29. de Castro MJ, Pardo-Seco J, Martinon-Torres F. Nonspecific (het- erologous) protection of neonatal BCG vaccination against hos- pitalization due to respiratory infection and sepsis. *Clin Infect Dis*. 2015;60(11):1611-1619.

**2**

1. PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. *Nat Immunol*. 2011;12(3):189-194.
2. Meeting of the Strategic Advisory Group of Experts on immuni- zation, April 2014—conclusions and recommendations. *Wkly Epidemiol Rec*. 2014;21:233-236. Available at: <[http://www](http://www.who.int/wer/2014/wer8921.pdf)

[.who.int/wer/2014/wer8921.pdf](http://www.who.int/wer/2014/wer8921.pdf)>.

1. Ritz N, Mui M, Balloch A, et al. Non-specific effect of Bacille Calmette-Guerin vaccine on the immune response to routine immunisations. *Vaccine*. 2013;31(30):3098-3103.
2. Jensen KJ, Larsen N, Biering-Sorensen S, et al. Heterologous immunological effects of early BCG vaccination in low-birth- weight infants in Guinea-Bissau: a randomized-controlled trial. *J Infect Dis*. 2015;211(6):956-967.
3. Kleinnijenhuis J, Quintin J, Preijers F, et al. BCG-induced trained immunity in NK cells: Role for non-specific protection to infec- tion. *Clin Immunol*. 2015;155(2):213-219.
4. Paust S, von Andrian UH. Natural killer cell memory. *Nat Immunol*. 2011;12(6):500-508.
5. Anderson EJ, Webb EL, Mawa PA, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. *Vaccine*. 2012;30(12):2083-2089.
6. Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. *J Innate Immun*. 2014;6(2): 152-158.
7. Kleinnijenhuis J, van Crevel R, Netea MG. Trained immunity: consequences for the heterologous effects of BCG vaccination. *Trans R Soc Trop Med Hyg*. 2015;109(1):29-35.
8. de Vries RD, McQuaid S, van Amerongen G, et al. Measles immune suppression: lessons from the macaque model. *PLoS Pathog*. 2012;8(8):e1002885.
9. de Vries RD, de Swart RL. Measles immune suppression: functional impairment or numbers game? *PLoS Pathog*. 2014;10(12):e1004482.
10. Mina MJ, Metcalf CJ, de Swart RL, et al. Vaccines. Long-term measles-induced immunomodulation increases overall child- hood infectious disease mortality. *Science*. 2015;348(6235): 694-699.
11. Aaby P, Nielsen J, Benn CS, et al. Sex-differential and non- specific effects of routine vaccinations in a rural area with low vaccination coverage: an observational study from Senegal. *Trans R Soc Trop Med Hyg*. 2015;109(1):77-84.
12. Thøstesen LM, Nissen TN, Kjærgaard J, et al. Bacillus Calmette- Guérin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial. *Contemp Clin Trials*. 2015;42:213-218.
13. UNICEF. *The State of the World’s Children 2009: Maternal and Newborn Health*. New York, NY: United Nations Children’s Fund; 2009.
14. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. *Nat Rev Immunol*. 2007;7:379-390.
15. Philbin VJ, Levy O. Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. *Pediatr Res*. 2009;65:98R-105R.
16. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. *Nat Rev Immunol*. 2009;9:185-194.
17. Pichichero ME. Challenges in vaccination of neonates, infants and young children. *Vaccine*. 2014;32(31):3886-3894.
18. Goenka A, Kollmann TR. Development of immunity in early life.

*J Infect*. 2015;71(suppl 1):S112-S120.

1. Kruschinski C, Zidan M, Debertin AS, et al. Age-dependent development of the splenic marginal zone in human infants is associated with different causes of death. *Hum Pathol*. 2004;35:113-121.
2. Siegrist CA. Neonatal and early life vaccinology. *Vaccine*. 2001;19:3331-3346.
3. Einhorn MS, Weinberg GA, Anderson EL, et al. Immunogenicity in infants of *Haemophilus influenzae* type B polysaccharide in a conjugate vaccine with *Neisseria meningitidis* outer-membrane protein. *Lancet*. 1986;2:299-302.
4. Slack MH, Schapira D, Thwaites RJ, et al. Responses to a fourth dose of *Haemophilus influenzae* type B conjugate vaccine in early life. *Arch Dis Child Fetal Neonatal Ed*. 2004;89:F269-F271.
5. Gans HA, Arvin AM, Galinus J, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. *JAMA*. 1998;280:527-532.
6. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. *JAMA*. 2004;291:851-855.
7. Siegrist CA. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. *Vaccine*. 2003;21:3406-3412.
8. Jones C, Pollock L, Barnett SM, et al. The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. *Vaccine*. 2014;32(8):996- 1002.
9. Amenyogbe N, Levy O, Kollmann TR. Systems vaccinology: a promise for the young and the poor. *Philos Trans R Soc Lond B Biol Sci*. 2015;370(1671), pii: 20140340.
10. Pihlgren M, Tougne C, Bozzotti P, et al. Unresponsiveness to lymphoid-mediated signals at the neonatal follicular dendritic cell precursor level contributes to delayed germinal center induc- tion and limitations of neonatal antibody responses to T-dependent antigens. *J Immunol*. 2003;170:2824-2832.
11. Mastelic B, Kamath AT, Fontannaz P, et al. Environmental and T cell-intrinsic factors limit the expansion of neonatal follicular T helper cells but may be circumvented by specific adjuvants. *J Immunol*. 2012;189(12):5764-5772.
12. Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adju- vant with influenza vaccine in young children. *N Engl J Med*. 2011;365(15):1406-1416.
13. Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. *Pediatrics*. 2003;111:1042-1045.
14. Knuf M, Schmitt HJ, Wolter J, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of per- tussis antibodies in infants. *J Pediatr*. 2008;152:655-660.e1.
15. Wood N, McIntyre P, Marshall H, et al. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. *Pediatr Infect Dis J*. 2010;29:209-215.
16. Halasa NB, O’Shea A, Shi JR, et al. Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. *J Pediatr*. 2008;153:327-332.
17. Knuf M, Schmitt HJ, Jacquet JM, et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. *J Pediatr*. 2010;156:675-678.
18. Siegrist CA. Blame vaccine interference, not neonatal immuniza- tion, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. *J Pediatr*. 2008;153: 305-307.
19. Tiru M, Hallander HO, Gustafsson L, et al. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. *Vaccine*. 2000;18:2295-2306.
20. Pihlgren M, Friedli M, Tougne C, et al. Reduced ability of neo- natal and early-life bone marrow stromal cells to support plas- mablast survival. *J Immunol*. 2006;176:165-172.
21. Longworth E, Borrow R, Goldblatt D, et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. *Vaccine*. 2002;20:2592-2596.
22. Pichichero ME, Voloshen T, Zajac D, et al. Avidity maturation of antibody to *Haemophilus influenzae* type b (Hib) after immuniza- tion with diphtheria-tetanus-acellular pertussis-Hib-hepatitis B combined vaccine in infants. *J Infect Dis*. 1999;180:1390-1393.
23. Goldblatt D, Richmond P, Millard E, et al. The induction of immunologic memory after vaccination with *Haemophilus influ- enzae* type b conjugate and acellular pertussis–containing diph- theria, tetanus, and pertussis vaccine combination. *J Infect Dis*. 1999;180:538-541.
24. Debock I, Flamand V. Unbalanced neonatal CD4(+) T-cell immunity. *Front Immunol*. 2014;5:393.
25. Vekemans J, Ota MO, Wang EC, et al. T cell responses to vaccines in infants: defective IFNgamma production after oral polio vac- cination. *Clin Exp Immunol*. 2002;127:495-498.
26. Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Hepatitis B immunisation induces higher antibody and memory Th2 responses in newborns than in adults. *Vaccine*. 2004;22: 511-519.
27. Rowe J, Macaubas C, Monger T, et al. Heterogeneity in diphtheria- tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th1 function. *J Infect Dis*. 2001;184:80-88.
28. White OJ, Rowe J, Richmond P, et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. *Vaccine*. 2010;28:2648-2652.
29. Goriely S, Vincart B, Stordeur P, et al. Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. *J Immunol*. 2001;166:2141-2146.
30. De Wit D, Olislagers V, Goriely S, et al. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. *Blood*. 2004;103:1030-1032.
31. Corbett NP, Blimkie D, Ho KC, et al. Ontogeny of Toll-like recep- tor mediated cytokine responses of human blood mononuclear cells. *PLoS ONE*. 2010;5:e15041.
32. Haines CJ, Giffon TD, Lu LS, et al. Human CD4+ T cell recent thymic emigrants are identified by protein tyrosine kinase 7 and have reduced immune function. *J Exp Med*. 2009;206:275-285.
33. Mold JE, Michaelsson J, Burt TD, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. *Science*. 2008;322:1562-1565.
34. Elahi S, Ertelt JM, Kinder JM, et al. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infec- tion. *Nature*. 2013;504(7478):158-162.
35. Vekemans J, Amedei A, Ota MO, et al. Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. *Eur J Immunol*. 2001;31: 1531-1535.
36. Simister NE. Placental transport of immunoglobulin G. *Vaccine*. 2003;21:3365-3369.
37. Albrecht P, Ennis FA, Saltzman EJ, et al. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. *J Pediatr*. 1977;91:715-718.
38. Jelonek MT, Maskrey JL, Steimer KS, et al. Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine. *J Infect Dis*. 1996;174: 866-869.
39. Kurikka S, Olander RM, Eskola J, et al. Passively acquired anti- tetanus and anti-*Haemophilus* antibodies and the response to *Haemophilus influenzae* type b–tetanus toxoid conjugate vaccine in infancy. *Pediatr Infect Dis J*. 1996;15:530-535.
40. Nohynek H, Gustafsson L, Capeding MR, et al. Effect of trans- placentally acquired tetanus antibodies on the antibody responses to *Haemophilus influenzae* type b–tetanus toxoid con- jugate and tetanus toxoid vaccines in Filipino infants. *Pediatr Infect Dis J*. 1999;18:25-30.
41. Ladhani S, Andrews NJ, Southern J, et al. Antibody responses after primary immunisation in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. *Clin Infect Dis*. 2015;61(11):1637-1644.
42. Kim D, Huey D, Oglesbee M. Insights into the regulatory mecha- nism controlling the inhibition of vaccine-induced seroconver- sion by maternal antibodies. *Blood*. 2011;117:6143-6151.
43. Niewiesk S. Maternal antibodies: Clinical significance, mecha- nism of interference with immune responses, and possible vac- cination strategies. *Front Immunol*. 2014;5:446.
44. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. *Pediatr Infect Dis J*. 2000;19:1045-1052.
45. Dagan R, Ashkenazi S, Amir J, et al. *High-dose inactivated hepatitis A vaccine (HD-HAV-VAC) in infants: comparison of response in the presence versus absence of maternally-derived antibodies (MatAb)*. Proceedings of the 38th Annual ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy); 1998. San Diego, California.
46. Cutts FT, Nyandu B, Markowitz LE, et al. Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month- old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. *Vaccine*. 1994;12:1311-1316.
47. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole- cell pertussis vaccines combined with diphtheria and tetanus toxoids. *Pediatrics*. 1995;96(3 Pt 2):580-584.
48. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in infants whose mothers received Tdap vaccine during preg- nancy. *Pediatr Infect Dis J*. 2013;32(11):1257-1260.
49. Pabst HF, Spady DW, Carson MM, et al. Cell-mediated and anti- body immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. *Vaccine*. 1999;17:1910-1918.
50. Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. *J Immunol*. 1999;162:5569-5575.
51. Rowe J, Poolman JT, Macaubas C, et al. Enhancement of vaccine- specific cellular immunity in infants by passively acquired mater- nal antibody. *Vaccine*. 2004;22:3986-3992.
52. PrabhuDas M, Adkins B, Gans H, et al. Challenges in infant immunity: implications for responses to infection and vaccines. *Nat Immunol*. 2011;12:189-194.
53. Weinberger B, Herndler-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. *Clin Infect Dis*. 2008;46:1078-1084.
54. LeMaoult J, Delassus S, Dyall R, et al. Clonal expansions of B lymphocytes in old mice. *J Immunol*. 1997;159:3866-3874.
55. Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. *Semin Immunol*. 2005;17:378-384.
56. Murasko DM, Bernstein ED, Gardner EM, et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. *Exp Gerontol*. 2002;37:427-439.
57. Gardner EM, Bernstein ED, Dran S, et al. Characterization of antibody responses to annual influenza vaccination over four years in a healthy elderly population. *Vaccine*. 2001;19:4610-4617.
58. Hainz U, Jenewein B, Asch E, et al. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. *Vaccine*. 2005;23:3232-3235.
59. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. *Clin Microbiol Rev*. 2003;16:308-318.
60. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biological disease-modifying antirheumatic drugs on antibody responses to the ASO3-adjuvanted pandemic influenza vaccine:

a prospective, open-label, parallel-cohort, single-center study.

*Arthritis Rheum*. 2011;63:1486-1496.

**2**

1. Weksler ME. Changes in the B-cell repertoire with age. *Vaccine*. 2000;18:1624-1628.
2. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against *Streptococcus pneumoniae* in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. *Clin Infect Dis*. 1999;29:281-288.
3. Chen WH, Kozlovsky BF, Effros RB, et al. Vaccination in the elderly: an immunological perspective. *Trends Immunol*. 2009;30:351-359.
4. Shi Y, Yamazaki T, Okubo Y, et al. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. *J Immunol*. 2005;175:3262-3267.
5. Luscieti P, Hubschmid T, Cottier H, et al. Human lymph node morphology as a function of age and site. *J Clin Pathol*. 1980;33:454-461.
6. Lottenbach KR, Mink CM, Barenkamp SJ, et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccina- tion. *Infect Immun*. 1999;67:4935-4938.
7. Burns EA, Lum LG, Seigneuret MC, et al. Decreased specific anti- body synthesis in old adults: decreased potency of antigen- specific B cells with aging. *Mech Ageing Dev*. 1990;53:229-241.
8. Linterman MA. How T follicular helper cells and the germinal centre response change with age. *Immunol Cell Biol*. 2014; 92(1):72-79.
9. Aydar Y, Balogh P, Tew JG, et al. Follicular dendritic cells in aging, a “bottle-neck” in the humoral immune response. *Ageing Res Rev*. 2004;3:15-29.
10. Zheng B, Han S, Takahashi Y, et al. Immunosenescence and germinal center reaction. *Immunol Rev*. 1997;160:63-77.
11. Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T cells. *Immunol Rev*. 1997;160: 55-62.
12. Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. *J Immunol*. 2004;173: 673-681.
13. Kovaiou RD, Weiskirchner I, Keller M, et al. Age-related differ- ences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. *Int Immunol*. 2005;17:1359-1366.
14. Deng Y, Jing Y, Campbell AE, et al. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. *J Immunol*. 2004;172:3437-3446.
15. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med*. 2014;371:635-645.